

Journal of Integrated

OMICS

a methodological journal

## Editors-in-Chief

Carlos Lodeiro-Espiño

Florentino Fdez-Riverola

Jens Coorsen

Jose-Luís Capelo-Martínez

# JIOMICS

## Journal of Integrated OMICS

---

### Focus and Scope

Journal of Integrated OMICS, JIOMICS, provides a forum for the publication of original research papers, preliminary communications, technical notes and critical reviews in all branches of pure and applied "-omics", such as genomics, proteomics, lipidomics, metabolomics or metallomics. The manuscripts must address methodological development. Contributions are evaluated based on established guidelines, including the fundamental nature of the study, scientific novelty, and substantial improvement or advantage over existing technology or method. Original research papers on fundamental studies, and novel sensor and instrumentation development, are especially encouraged. It is expected that improvements will also be demonstrated within the context of (or with regard to) a specific biological question; ability to promote the analysis of molecular mechanisms is of particular interest. Novel or improved applications in areas such as clinical, medicinal and biological chemistry, environmental analysis, pharmacology and materials science and engineering are welcome.

### Editors-in-Chief

**Carlos Lodeiro-Espiño**, University NOVA of Lisbon, Portugal

**Florentino Fdez-Riverola**, University of Vigo, Spain

**Jens R. Coorsen**, University of Western Sydney, NSW, Australia

**Jose-Luís Capelo-Martínez**, University NOVA of Lisbon, Portugal

### Regional editors

#### ASIA

##### **Gary Xiao**

Director of Functional Genomics and Proteomics Laboratories at Osteoporosis Research Center, Creighton University Omaha, Nebraska, USA

##### **Yogeshwer Shukla**

Proteomics laboratory at Indian Institute of Toxicology Research (Council of Scientific and Industrial Research), Lucknow, India

#### AUSTRALIA AND NEW ZEALAND

##### **Jens R. Coorsen**

University of Western Sydney, NSW, Australia

#### Europe

##### **Gilberto Igrejas**

University of Trás-os-Montes and Alto Douro, Life Sciences and Environmental School, Institute for Biotechnology and Bioengineering, Centre of Genetics and Biotechnology  
Department of Genetics and Biotechnology, 5001-801 Vila Real, Portugal

##### **Martin von Bergen**

UFZ, Helmholtz-Centre for Environmental Research, Department of Proteomics, Permoserstr. 15, 04318 Leipzig, Germany

##### **Jan Ottervald**

Research and Development | Innovative Medicines Neuroscience, CNSP iMed Science Södertälje, AstraZeneca, Sweden

## North America

---

### **Randen Patterson**

Center for Computational Proteomics, The Pennsylvania State University, USA

### **Oscar Alzate**

Associate Professor of Cell and Developmental Biology, Adjunct Associate Professor in Neurology, Director: Systems Proteomics Center

School of Medicine, The University of North Carolina at Chapel Hill, USA

### **Yue Ge**

US Environmental Protection Agency, Research Triangle Park, USA

## South America

---

### **Eduardo Alves de Almeida**

Depto. de Química e Ciências Ambientais, IBILCE - UNESP, Brazil

### **Marco Aurélio Zezzi Arruda**

University of Campinas - Unicamp

### **Carlos H. I. Ramos**

Chemistry Institute – UNICAMP, Brazil

## Associated editors

### AFRICA

---

#### **Saffaj Taouqif**

Centre Universitaire Régional d'Interface, Université Sidi Mohamed Ben Abdallah, route d'Imouzzar-Fès, Morocco

### ASIA

---

#### **Abdul Jaleel A**

Rajiv Gandhi Centre for Biotechnology, Thycaud PO, Trivandrum, Kerala, India

#### **Ali A. Ensafi**

Isfahan University of Technology, Iran

#### **Allison Stelling**

Dresden, Germany

#### **Amita Pal**

Division of Plant Biology, Bose Institute, Kolkata, India

#### **Ashish Gupta**

Centre of Biomedical Magnetic Resonance, SGPGIMS Campus, Lucknow, India

#### **Canhua Huang**

The State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, PR China

#### **Chaminda Jayampath Seneviratne**

Oral Biosciences, Faculty of Dentistry, University of Hong Kong, Hong Kong

#### **Cheolju Lee**

Korea Institute of Science and Technology, Seoul, Korea

#### **Chi Chiu Wang**

Department of Obstetrics & Gynaecology, Chinese University of Hong Kong, Hong Kong

#### **Chii-Shiarng Chen**

National Museum of Marine Biology and Aquarium, Checheng, Pingtung, Taiwan

#### **Ching-Yu Lin**

Institute of Environmental Health, College of Public Health, National Taiwan University, Taipei, Taiwan

#### **Chantragan Srisomsap**

Chulabhorn Research Institute, Bangkok, Thailand

#### **Chen Han-Min**

Department of Life Science, Catholic Fu-Jen University, Taipei, Taiwan

#### **David Yew**

Chinese University of Hong Kong, Shatin, N.T., Hong Kong

#### **Debmalya Barh**

Institute of Integrative Omics and Applied Biotechnology (IIOAB), India

#### **Dwaipayan Bharadwaj**

Genomics & Molecular Medicine Unit, Institute of Genomics & Integrative Biology (CSIR), Mall Road, Delhi, India

#### **Eiji Kinoshita**

Department of Functional Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, Japan

#### **Eun Joo Song**

Molecular Recognition Research Center, Korea Institute of Science & Technology, Seoul, Korea

#### **Fan Chen**

Institute of Genetics and Developmental Biology, Chinese Academy of Sciences (CAS), China

#### **Feng Ge**

Institute of Hydrobiology, Chinese Academy of Sciences, China

#### **Ganesh Chandra Sahoo**

BioMedical Informatics Center of Rajendra Memorial Research Institute of Medical Science (RMRIMS), Patna, India

#### **Guangchuang Yu**

Institute of Life & Health Engineering, Jinan University, Guangzhou, China

#### **Gufeng Wang**

Department of Chemistry, North Carolina State University, Raleigh, USA

#### **Hai-Lei Zheng**

School of Life Sciences, Xiamen University, China

#### **Hee-bal Kim**

Department of Food and Animal Biotechnology of the Seoul National University, Korea

#### **Hsin-Yi Wu**

Institute of Chemistry, Academia Sinica, Taiwan

#### **Hitoshi Iwahashi**

Health Research Institute, National Institute of Advanced Industrial Science

and Technology (AIST), Japan

**Hong-Lin Chan**

National Tsing-Hua University, Taiwan

Hongying Zhong

College of Chemistry, Central China Normal University, Wuhan, P. R. China

**Huan-Tsung Chang**

Department of Chemistry, National Taiwan University, Taipei, Taiwan

**HuaXu**

Research Resources Center, University of Illinois, Chicago

**Hui-Fen Wu**

Department of Chemistry, National Sun Yat – Sen University, 70, Lien-Hai Road, 80424, Kaohsiung, Taiwan

**Hye-Sook Kim**

Faculty of Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan

**Hyun Joo An**

ChungNam National University, Daejeon, Korea (South)

**Ibrokhir Abdurakhmonov**

Institute of Genetics and Plant experimental Biology Academy of Sciences of Uzbekistan, Uzbekistan

**Isam Khalaila**

Biotechnology Engineering Department, Ben-Gurion University, Israel

**Jagannadham Medicharla**

Senior Principal Scientist, CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India

**Jianghao Sun**

Food Composition and Method Development Lab, U.S. Dept. of Agriculture, Agricultural Research Services, Beltsville, USA

**Jong Won Yun**

Dept. of Biotechnology, Kyungsan, Kyungbuk 712-714, Republic of Korea

**Juan Emilio Palomares-Rius**

Forestry and Forest Products Research Institute, Tsukuba, Japan

**Jung Min Kim**

Liver and Immunology Research Center, Daejeon Oriental Hospital of Daejeon University, Republic of Korea

**Kazuaki Kakehi**

School of Pharmacy, Kinki University, Kowakae 3-4-1, Higashi-Osaka, 577-8502, Japan

**Kazuki Sasaki**

Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Japan

**Ke Lan**

West China School of Pharmacy, Sichuan University, Chengdu, China

**Kelvin Leung**

Department of Chemistry, Hong Kong Baptist University, Hong Kong

**Kobra Pourabdollah**

Razi Chemistry Research Center (RCRC), Shahreza Branch, Islamic Azad University, Shahreza, Iran

**Kohji Nagano**

Chugai Pharmaceutical Co. Ltd., Japan

**Koji Ueda**

Laboratory for Biomarker Development, Center for Genomic Medicine, RIKEN, Tokyo, Japan

**Krishnakumar Menon**

Amrita Center for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences, Kochi, Kerala, India

**Lakshman Samaranayake**

Dean, And Chair of Oral Microbiology, University of Hong Kong, Hong Kong

**Lal Rai**

Molecular Biology Section, Centre of Advanced Study in Botany, Banaras Hindu University, Varanasi-221005, India

**Lei Zhou**

Singapore Eye Research Institute, Singapore

**Li Jianke**

Institute of Apicultural Research, Chinese Academy of Agricultural Science, Beijing, China, HKSAR, PR China

**Ling Zheng**

College of Life Sciences, Wuhan University, China

**Luk John Moonching**

National University of Singapore, Singapore

**Mahdi Ghasemi-Varnamkhasti**

Department of Agricultural Machinery Engineering, Faculty of Agriculture, Shahrekord University, Shahrekord, Iran

**Manjunatha Kini**

Department of Biological Sciences, National University of Singapore, Singapore

**Masahiro Sugimoto**

Graduate School of Medicine and Faculty of Medicine, Kyoto University Medical Innovation Center, Japan

**Masaya Miyazaki**

National Institute of Advanced Industrial Science and Technology, 807-1 Shuku, Tosu, Saga 841-0052, Japan

**Ming-Fa Hsieh**

Department of Biomedical Engineering, Chung Yuan Christian University, Taiwan

**Mingfeng Yang**

Key Laboratory of Urban Agriculture of Ministry of Agriculture P. R. China Beijing University of Agriculture, China

**Mo Yang**

Interdisciplinary Division of Biomedical Engineering, the Hong Kong Polytechnic University, Hong Kong, China

**Mohammed Rahman**

Center of Excellence for Advanced Materials Research (CEAMR), King Abdulaziz University, Jeddah, Saudi Arabia

**Moganty Rajeswari**

Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

**Nam Hoon Cho**

Dept. of Pathology, Yonsei University College of Medicine, Korea

**Ningwei Zhao**

Life Science & Clinical Medicine Dept. ; Shimadzu (China) Co., Ltd

**Pei-Yuan Qian**

Division of Life Science, Hong Kong University of Science and Technology, China

**Peng Zhou**

Center of Bioinformatics (COBI), Key Laboratory for NeuroInformation of Ministry of Education (KLNME), University of Electronic Science and Technology of China (UESTC)

**Poh-Kuan CHONG (Shirly)**

National University of Singapore, Singapore

**Qian Shi**

Institutes of Biomedical Sciences, Fudan University, Shanghai, China

**Qionglian Liang**

Tsinghua University, Beijing, China

**Rakesh Mishra**

Centre for Cellular and Molecular Biology, Hyderabad, India

**Roger Beuerman**

Singapore Eye Research Institute, Singapore

**Sameh Magdeldin Mohamed**

Niigata prefecture, Nishi-ku, Terao, Niigata, Japan

**Sanjay Gupta**

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India

**Sanjeeva Srivastava**

Indian Institute of Technology (IIT) Bombay, India

**Seiichi Uno**

Education and Research Center for Marine Resources and Environment,  
Faculty of Fisheries, Kagoshima University, Japan

**Sen-Lin Tang**

Biodiversity Research Center, Academia Sinica, Taipei, Taiwan

**Setsuko Komatsu**

National Institute of Crop Science, Japan

**Shaojun Dai**

Alkali Soil Natural Environmental Science Center, Key Laboratory of Saline-alkali Vegetation Ecology Restoration in Oil Field, Ministry of Education, Northeast Forestry University, P.R. China

**Shipin Tian**

Institute of Botany, Chinese Academy of Sciences, China

**Songping Liang**

Hunan Normal University, Changsha City, China

**Steven Shaw**

Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou, Taiwan

**Suresh Kumar**

Department of Applied Chemistry, S. V. National Institute of Technology, Gujarat, India

**Tadashi Kondo**

National Cancer Center Research Institute, Japan

**Taesung Park**

National Research Laboratory of Bioinformatics and Biostatistics at the Department of Statistics Seoul National University, Korea

**Toshihide Nishimura**

Department of Surgery I, Tokyo Medical University, Tokyo, Japan

**Vishvanath Tiwari**

Department of Biochemistry, Central University of Rajasthan, India

**Wei Wang**

School of Medical Sciences, Edith Cowan University, Perth, Australia

**Weichuan Yu**

Department of Electronic and Computer Engineering and Division of Biomedical Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China

**Wei-dong Zhang**

Lab of Natural Products, School of Pharmacy, Second Military Medical University, Shanghai, China

**Wenxiong Lin**

School of Life Sciences, Fujian Agriculture and Forestry University, China

**William Chen Wei Ning**

School of Chemical and Biomolecular Engineering Nanyang Technological University, Singapore

**Xiao LiWang**

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

**Xiao Zhiqiang**

Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha,

Hunan 410008, P.R. China

**Xiaoping Wang**

Key Laboratory of Molecular Biology & Pathology, State Bureau of Chinese Medicine, China

**Xuanxian Peng**

School of Life Sciences, Sun Yat-sen University, Guangzhou, China

**Yang Liu**

Department of Chemistry, Tsinghua University, Beijing, China

**YasminAhmad**

Peptide and Proteomics Division Defence Institute of Physiological and Allied Research (DIPAS), DRDO, Ministry of Defence, Timarpur, Delhi-54, India

**Yin Li**

Institute of Microbiology, Chinese Academy of Sciences, Beijing, China

**Yong Song Gho**

Department of Life Science, POSTECH, Pohang, Korea

**Yoon-E Choi**

Chonbuk National University, Iksan-si, South Korea

**Yoon-Pin Lim**

Department of Biochemistry, National University of Singapore, Singapore

**Young-Gyu Ko**

College of Life Sciences and Biotechnology, Korea University, Korea

**Young-Suk Kim**

Department of Food Science and Engineering, College of Engineering, Ewha Womans University, Seoul, Korea

**Youngsoo Kim**

Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea

**Youxiong Que**

National Research & Development Center for Sugarcane, China Agriculture Research System(CARS), Fujian Agriculture & Forestry University, Republic of China

**Yu-Chang Tyan**

Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan

**Yu Wang**

Department of Pharmacology and Pharmacy, the University of Hong Kong, China

**Yu Xue**

Department of Systems Biology, College of Life Science and Technology Huazhong University of Science and Technology, Wuhan, China

**Yulan Wang**

State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Wuhan Centre for Magnetic Resonance, Wuhan Institute of Physics and Mathematics, The Chinese Academy of Sciences, China

**Zhengwei Yuan**

The key laboratory of health ministry for congenital malformation, Shengjing Hospital, China Medical University

**Zhiqiang Gao**

Department of Chemistry, National University of Singapore

**AUSTRALIA AND NEW ZEALAND**

---

**Bruno Catimel**

Epithelial laboratory, Ludwig Institute for Cancer Research, Post Office Royal Melbourne Hospital, Australia

**Daniel Cozzolino**

Barley Research Laboratory, School of Agriculture, Food and Wine, University of Adelaide, Australia

**David Beale**

CSIRO Land and Water, Highett, Australia

**Emad Kiriakous**

Queensland University of Technology (QUT), Brisbane, Australia

**Joëlle Coumans-Moens**

School of Science and Technology, School of Medicine, University of New England, Australia

**Marc Wilkins**

University of New South Wales, Sydney, Australia

**Maurizio Ronci**

Mawson Institute, University of South Australia, Mawson Lakes, Australia

**Michelle Hill**

University of Queensland, Australia

**Michelle Colgrave**

CSIRO Livestock Industries, St Lucia, Australia

**Nicolas Taylor**

ARC Centre of Excellence in Plant Energy Biology & Centre for Comparative Analysis of Biomolecular Networks (CABiN), University of Western Australia, Perth, Australia

**Peter Hoffmann**

Institute for Photonics & Advanced Sensing (IPAS), School of Chemistry and Physics, University of Adelaide, Australia

**Stefan Clerens**

Protein Quality & Function, AgResearch Ltd Christchurch, New Zealand

**Peter Solomon**

Research School of Biology College of Medicine, Biology and Environment, Australian National University, Australia

**Phoebe Chen**

Department of Computer Science and Computer Engineering, La Trobe University, Melbourne, Australia

**Richard Christopherson**

School of Molecular Bioscience, University of Sydney, Australia

**Sham Nair**

Department of Biological Sciences, Faculty of Science, Macquarie University, NSW, Australia

**Sylvia Urban**

School of Applied Sciences (Discipline of Applied Chemistry), RMIT University, Melbourne, Victoria, Australia

**Valerie Wasinger**

Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, University of NSW, Australia

**Wujun Ma**

Centre for Comparative Genomics, Murdoch University, Australia

**Yin Xiao**

Institute of Health and Biomedical Innovation, Queensland University of Technology, Australia

EUROPE

---

**AhmetKoc, PhD**

Izmir Institute of Technology, Department of Molecular Biology & Genetics, Urla, İzmir, Turkey

**Alejandro Gella**

Department of Basic Sciences, Neuroscience Laboratory, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès-08195, Barcelona, Spain

**Alessandro Pessione**

Università degli Studi di Torino, Italy

**Alexander Scherl**

Proteomics Core Facility, Faculty of Medicine, University of Geneva, Geneva, Switzerland

**Alfio Ferlito**

ENT Clinic, University of Udine, Italy

**Almudena Fernández Briera**

Dpt. Biochemistry Genetics and Immunology, Faculty of Biology –University of Vigo, Spain

**Alfonsina D'Amato**

Politecnico di Milano, Department of Chemistry, Materials and Chemical Engineering "GiulioNatta", Italy

**Alfred Vertegaal**

Molecular Cell Biology, Leiden University Medical Center, The Netherlands

**Ali Mobasher**

School of Veterinary Medicine and Science, Faculty of Medicine and Health Sciences, University of Nottingham, Sutton Bonington Campus, Sutton Bonington, Leicestershire, United Kingdom

**Andre Almeida**

Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Portugal

**Andrea Matros**

Leibniz Institute of Plant Genetics and Crop Plant Research (IPK-Gatersleben), Gatersleben, Germany

**Andrei Turtoi**

University of Liege, Metastasis Research Laboratory, GIGA-Cancer Bât. B23, Belgium

**Angelo D'Alessandro**

Università degli Studi della Tuscia, Department of Ecological and Biological Sciences, Viterbo, Italy

**Angelo Izzo**

Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy

**Antonio Gnoni**

Department of Medical Basic Sciences, University of Bari "Aldo Moro", Bari, Italy

**Ana Maria Rodríguez-Piñeiro**

Institute of Biomedicine, University of Gothenburg, Sweden

**Ana Varela Coelho**

Instituto de Tecnologia Química e Biológica (ITQB) Universidade Nova de Lisboa (UNL), Portugal

**Anna Maria Timperio**

Dipartimento Scienze Ambientali Università della Tuscia Viterbo, Italy

**André Nogueira Da Costa**

Molecular Carcinogenesis Group, Section of Mechanisms of Carcinogenesis International Agency for Research on Cancer - World Health Organization (IARC-WHO), Lyon, France

**Andreas Boehm**

Steigerfurtweg 8a, D-97084 Würzburg, Germany

**Andrea Scaloni**

Proteomics and Mass Spectrometry Laboratory, ISPAAM, National Research Council, via Argine 1085, 80147 Napoli, Italy

**Andreas Tholey**

Division for Systematic Proteome Research, Institute for Experimental Medicine, Christian-Albrechts-University, Germany

**Angel Manteca**

Departamento de Biología Funcional and IUBA, Facultad de Medicina, Universidad de Oviedo, Spain

**Angel P. Diz**

Department of Biochemistry, Genetics and Immunology, Faculty of Biology, University of Vigo, Spain

**Angela Bachi**

Mass Spectrometry Unit DIBIT, San Raffaele Scientific Institute, Milano, Italy

**Angela Chambery**

Department of Life Science, Second University of Naples, Italy

**Anna-Irini Koukkou**

University of Ioannina, Department of Chemistry, Biochemistry Laboratory, Greece

**António Sebastião Rodrigues**

Departamento de Genética, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Portugal

**Arkadiusz Kosmala**

Laboratory of Cytogenetics and Molecular Biology, Institute of Plant Genetics, Polish Academy of Sciences, Poland

**Arzu Umar**

Department of Medical Oncology, Laboratory of Breast Cancer Genomics and Proteomics, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands

**Baggerman Geert**

ProMeta, Interfaculty Center for Proteomics and Metabolomics, Leuven, Belgium

**Bart De Spiegeleer**

Ghent University, Belgium

**Bart Devreese**

Laboratory for Protein Biochemistry and Biomolecular Engineering, Department for Biochemistry and Microbiology, Ghent University, Belgium

**Bernard Corfe**

Department of Oncology, University of Sheffield, Royal Hallamshire Hospital, United Kingdom

**Bernd Thiede**

Biotechnology Centre of Oslo, University of Oslo, Blindern, Norway

**Björn Meyer**

Institut für Instrumentelle Analytik und Bioanalytik Hochschule Mannheim, Germany

**Bruno Baudin**

Biochemistry Laboratory A, Saint-Antoine Hospital, Hôpitaux Universitaires Est Parisien-APHP, Paris, France

**Bruno Manadas**

Center for Neuroscience and Cell Biology, University of Coimbra, Portugal

**Cândido Pinto Ricardo**

Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Av. da República-EAN, 2780-157 Oeiras, Portugal

**Carla Pinheiro**

Plant Sciences Division, Instituto de Tecnologia Química e Biológica (ITQB), Universidade Nova de Lisboa, Portugal

**Claudia Desiderio**

Consiglio Nazionale delle Ricerche, Istituto di Chimica del Riconoscimento Molecolare (UOS Roma), Italy

**Claudio De Pasquale**

SAGa Department, University of Palermo, Italy

**Carlos Gutiérrez Merino**

Dept. Biochemistry and Molecular Biology University of Extremadura, Badajoz, Spain

**Cecilia Calado**

Engineering Faculty Catholic University of Portugal, Rio de Mouro, Portugal

**Celso Reis**

Institute of Molecular Pathology and Immunology of the University of Porto, IPATIMUP, Portugal

**Celso Vladimiro Cunha**

Medical Microbiology Department, Institute of Hygiene and Tropical Medicine, New University of Lisbon, Portugal

**Charles Steward**

The Wellcome Trust Sanger Institute, Hinxton, United Kingdom

**Chris Goldring**

Department of Pharmacology and Therapeutics, MRC Centre for Drug Safety Science, University of Liverpool, United Kingdom

**Christian Lindermayr**

Institute of Biochemical Plant Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

**Christiane Fæste**

Section for Chemistry and Toxicology Norwegian Veterinary Institute, Oslo, Norway

**Christer Wingren**

Department of Immunotechnology, Lund University, Lund, Sweden

**Christophe Cordella**

UMR1145 INRA, Laboratoire de Chimie Analytique, Paris, France

**Christophe Masselon**

Laboratoire de Biologie a Grande Echelle (iRTSV/BGE), CEA Grenoble, France

**Cosima Damiana Calvano**

Universita' degli Studi di Bari, Dipartimento di Chimica, Bari, Italy

**David Cairns**

Section of Oncology and Clinical Research, Leeds Institute of Molecular Medicine, Leeds, UK

**Daniela Cecconi**

Dip. di Biotecnologie, Laboratori di Proteomica e Spettrometri di Massa, Università di Verona, Verona, Italy

**David Honys**

Laboratory of Pollen Biology, Institute of Experimental Botany ASCR, Czech Republic

**David Sheehan**

Dept. Biochemistry, University College Cork (UCC), Ireland

**Deborah Penque**

Departamento de Genética, Instituto Nacional de Saúde Dr Ricardo Jorge (INSA, I.P.), Lisboa, Portugal

**Dilek Battal**

Mersin University, Faculty of Pharmacy, Department of Toxicology, Turkey

**Domenico Garozzo**

CNR ICTP, Catania, Italy

**Ed Dudley**

Institute of Mass Spectrometry, College of Medicine Swansea University, Singleton Park, Swansea, Wales, UK

**Edoardo Saccenti**

University of Amsterdam, Netherlands Metabolomics Centre, The Netherlands

**Elena Gonzalez**

Complutense University of Madrid, Dept. Biochemistry and Molecular Biology IV, Veterinary Faculty, Madrid, Spain

**Elia Ranzato**

Dipartimento di Scienze e Innovazione Tecnologica, DiSIT, University of Piemonte Orientale, Alessandria, Italy

**Elisa Bona**

Università del Piemonte Orientale, DiSIT, Alessandria, Italy

**Elke Hammer**

Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt Universität, Germany

**Enrica Pessione**

University of Torino, Life Sciences and Systems Biology Department, Torino, Italy

**Eva Rodríguez Suárez**

Proteomics Core Facility - CIC bioGUNE, Parque tecnologico de Bizkaia, Spain

**Federica Pellati**

Department of Life Sciences, University of Modena and Reggio Emilia, Italy

**Ferdinando Cerciello**

Laboratory of Molecular Oncology, Clinic of Oncology, University Hospital Zürich, Switzerland

**Fernando J. Corrales**

Division of Hepatology and Gene Therapy, Proteomics Unit, Center for Applied Medical Research (CIMA), Pamplona, Spain

**Florian Szabados**

Dept. of Medical Microbiology, Ruhr-University Bochum, Germany

**Francesco Salii**

University of Milano Bicocca, Italy

**Francisco J Blanco**

Platform of Proteomics, Proteo-Red-ISCIH INIBIC-Hospital Universitario A Coruña, Spain

**Francisco Javier Fernández Acero**

Laboratory of Microbiology, Marine and Environmental Sciences Faculty, University of Cádiz, Pol. Río San Pedro s/n, Puerto Real, Cádiz, Spain

**Francisco Torrens**

Institut Universitari de Ciència Molecular, Universitat de València, Spain

**François Fenaille**  
CEA, IBItecS, Service de Pharmacologie et D'Immunoanalyse (SPI), France

**Frederic Silvestre**  
University of Namur, Belgium

**Fulvio Magni**  
Department of Health Science, Monza, Italy

**Georgios Theodoridis**  
Department of Chemistry, Aristotle University, Greece

**Germain Rousselet**  
Laboratoire Réparation et Transcription dans les cellules Souches (LRTS), CEA/DSV/IRCM, Fontenay aux Roses, France

**German Bou**  
Servicio de Microbiología-INIBIC, Complejo Hospitalario Universitario La Coruña, Spain

**Gianfranco Mamone**  
Proteomic and Biomolecular Mass Spectrometry Centre, Institute of Food Science CNR, Italy

**Gianfranco Romanazzi**  
Department of Environmental and Crop Sciences, Marche Polytechnic University, Italy

**Gianluigi Mauriello**  
Department of Food Science, University of Naples Federico II Naples, Italy

**Giorgio Valentini**  
Università degli Studi di Milano, Dept. of Computer Science, Italy

**Giuseppe Palmisano**  
Department of Biochemistry and Molecular Biology  
University of Southern Denmark, Odense M, Denmark

**Helen Gika**  
Chemical Engineering Department, Aristotle University of Thessaloniki, Greece

**Hugo Miguel Baptista Carreira dos Santos**  
REQUIMTE-FCT Universidade NOVA de Lisboa, Portugal

**Ignacio Casal**  
Functional Proteomics Laboratory, Centro de Investigaciones Biológicas (CSIC), Madrid, Spain

**Ignacio Ortea**  
European Commission, Joint Research Center, Institute for Reference Materials and Measurements, Geel, Belgium

**Iñaki Álvarez**  
Institut de Biotecnologia i Biomedicina Vicent Villar Palasí, Universitat Autònoma de Barcelona, Barcelona

**Isabel Marcelino**  
Instituto de Tecnologia Química e Biológica, Oeiras, Portugal

**Isabel Liste**  
Area de Biología Celular y del Desarrollo, Instituto de Salud Carlos III, Madrid, Spain

**Isabelle Fournier**  
University Lille Nord de France, Fundamental & Applied Biological Mass Spectrometry - EA 4550, Villeneuve d'Ascq, France

**Jacek Z. Kubiak**  
CNRS UMR 6061, University of Rennes 1, Institute of Genetics and Development of Rennes, Rennes, France

**Jane Thomas-Oates**  
Centre of Excellence in Mass Spectrometry and Department of Chemistry, University of York, Heslington, UK

**Jatin Burniston**  
Muscle Physiology and Proteomics Laboratory, Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Tom Reilly Building, Liverpool, United Kingdom

**Jean-Paul Issartel**  
INSERM U836, Grenoble Institut des Neurosciences, La Tronche, France

**Jens Allmer**  
Molecular Biology and Genetics, Izmir Institute of Technology, Urla, Izmir, Turkey

**Jerry Thomas**  
Technology Facility, Department of Biology, University of York, UK

**Jesús Jorrín Novo**  
Agricultural and Plant Biochemistry, Proteomics Research Group, Department of Biochemistry and Molecular Biology, Córdoba, Spain

**Jesús Mateos Martín**  
Osteoarticular and Aging Research Lab, Proteomics Unit INIBIC-Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain

**Joan Cerdà**  
Laboratory IRTA, Institute of Marine Sciences (CSIC), Passeig marítim 37-49, 08003 Barcelona, Spain

Joan Claria  
Department of Biochemistry and Molecular Genetics, Hospital Clínic of Barcelona, Spain

**João Rodrigues**  
Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal

**Joaquim ROS**  
Dept. Ciències Mèdiques Bàsiques. IRB Lleida. University of Lleida, Spain

**Joerg Reinders**  
AG Proteomics, Institute of Functional Genomics, University Regensburg, Germany

**Johan Palmfeldt**  
Research Unit for Molecular Medicine, Aarhus University Hospital, Skejby, Aarhus, Denmark

**Jose Andrés Fernández González**  
Universidad del País Vasco, Facultad de Ciencia y Tecnología, Spain

**Jose Câmara**  
University of Madeira, Funchal, Portugal

**Jose Cremata Alvarez**  
Department of Carbohydrate Chemistry, Center for Genetic Engineering and Biotechnology, Havana, Cuba

**Jose Luis Martín-Ventura**  
IIS-FJD-UAM, Madrid, Spain

**José Manuel Bautista**  
Departamento de Bioquímica y Biología Molecular IV, Universidad Complutense de Madrid, Spain

**Jose Manuel Palma**  
Departamento de Bioquímica, Biología Celular y Molecular de Plantas Estacion Experimental del Zaidin, CSIC, Granada, Spain

**José Moreira**  
Danish Center for Translational Breast Cancer Research, Denmark

**Juraj Gregan**  
Max F. Perutz Laboratories, University of Vienna, Austria

**Karin Stensjö**  
Department of Photochemistry and Molecular Science, Ångström laboratory, Uppsala University, Sweden

**Kathleen Marchal**  
CMPG/Bioinformatics, Dep Microbial and Molecular Systems, Leuven, Germany

**Kay Ohlendieck**  
Department of Biology, National University of Ireland, Maynooth, Co. Kildare, Ireland

**Keiryn Bennett**  
CeMM - Center for Molecular Medicine of the Austrian Academy of Sciences Vienna, Austria

**Kjell Sergeant**  
Centre de Recherche Public-Gabriel Lippmann, Department 'Environment and Agro-biotechnologies' (EVA), Luxembourg



**Konstantinos Kouremenos**

Department of Chemistry, Umea University, Sweden

**Lennart Martens**

Department of Medical Protein Research, VIB and Department of Biochemistry, Ghent University, Belgium

**Luis P. Fonseca**

Instituto Superior Técnico, Centro de Engenharia Biológica e Química, Institute for Biotechnology and Bioengineering, Lisboa, Portugal

**Luisa Brito**

Laboratório de Microbiologia, Instituto Superior de Agronomia, Tapada da Ajuda, Lisbon, Portugal

**Luisa Mannina**

CNR, Istituto di Metodologie Chimiche, Rome, Italy

**Manuel Avilés Sanchez**

Department of Cell Biology and Histology, School of Medicine, University of Murcia, Spain

**Mar Vilanova**

Misión Biológica de Galicia, Consejo Superior de Investigaciones Científicas, Pontevedra, Spain

**Marcello Donini**

ENEA -Casaccia Research Center, UTBIORAD-FARM, Biotechnology Laboratory, Italy

**Marco Lemos**

GIRM & ESTM - Polytechnic Institute of Leiria, Peniche, Portugal

**Marcus Mau**

King's College London, UK

**María Álava**

Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, Spain

Maria De Angelis

Department of Soil, Plant and Food Science, University of Bari Aldo Moro, Italy

**María de la Fuente**

Legume group, Genetic Resources, Mision Biologica de Galicia-CSIC, Pontevedra, Spain

**María M. Malagón**

Department of Cell Biology, Physiology and Immunology, IMIBIC, Universidad de Córdoba, Spain

**Maria Gabriela Rivas**

REQUIMTE/CQFB, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Portugal

**María Mayán**

INIBIC, LaCoruña, Spain

**María Páez de la Cadena**

Department of Biochemistry, Genetics and Immunology, University of Vigo, Spain

**Marie Arul**

Muséum National Histoire Naturelle, Département RDDM, Plateforme de spectrométrie de masse et de protéomique, Paris, France

**Marie-Pierre Bousquet**

Institut de Pharmacologie et de Biologie Structurale, UPS/CNRS, Toulouse, France

**Mario Diniz**

Dept. Química-REQUIMTE, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Portugal

Mark Davey

Catholic University of Leuven (KU Leuven), Belgium

**Marko Radulovic**

Institute for Oncology and Radiology, Laboratory of Cancer Cell biology, Belgrade, Serbia

**Martin Hajduch**

Department of Reproduction and Developmental Biology, Institute of Plant Genetics and Biotechnology, Slovak Academy of Sciences, Nitra, Slovakia

**Martin Kussmann**

Faculty of Science, Aarhus University, Aarhus, Denmark

**Martina Marchetti-Deschmann**

Institute of Chemical Technologies and Analytics, Vienna University of Technology, Vienna, Austria

**Maxence Wisztorski**

University Lille 1, Laboratoire de Spectrométrie de Masse Biologique, Fondamentale & Appliquée, Villeneuve d'Ascq, France

**Meri Hovsepyan**

Institute of Molecular Biology of Armenian National Academy of Sciences Yerevan, Armenia

**Michalis Nikolaidis**

Department of Physical Education and Sports Science at Serres, Aristotle University of Thessaloniki, Greece

**Michel Jaquinod**

Exploring the Dynamics of Proteomes/Laboratoire Biologie à Grande Echelle, Institut de Recherches en Technologies et Sciences pour le Vivant, Grenoble, France

**Michel Salzet**

Laboratoire de Spectrométrie de Masse Biologique Fondamentale et Appliquée, INSERM, Villeneuve d'Ascq, France

**Miguel Reboiro Jato**

Escuela Superior de Ingeniería Informática, Ourense, Spain

**Moncef Mrabet**

Laboratory of Legumes (LL), Centre of Biotechnology of Borj-Cédria (CBCB), Hammam-Lif, Tunisia

**Mónica Botelho**

Centre for the study of animal sciences (CECA)/ICETA, Porto, Portugal

**Monica Carrera**

Institute of Molecular Systems Biology, Zurich, Germany

**Okay Saydam**

Molecular Oncology Laboratory, Division of Neuro-Oncology, Department of Pediatrics Medical University of Vienna, Austria

**Ola Söderberg**

Department of Immunology, Genetics and Pathology, Uppsala University, Sweden

**Paloma Sánchez-Bel**

Dpto. Biología del estrés y Patología vegetal, CEBAS-CSIC, Murcia, Spain

**Pantelis Bagos**

Department of Computer Science and Biomedical Informatics, University of Central Greece, Greece

**Paolo Destefanis**

Department of Urology, "San Giovanni Battista - Molinette" Hospital, Turin, Italy

**Pasquale Vito**

Università del Sannio, Benevento, Italy

**Patrice Francois**

Genomic Research Laboratory, Service of Infectious Diseases, Department of Internal Medicine, Geneva

**Patrícia Alexandra Curado Quintas Dinis Poeta**

University of Trás-os-Montes and Alto Douro (UTAD), School of Agrary and Veterinary Sciences, Veterinary, Science Department, Portugal

**Paul Cutler**

F Hoffman La Roche, Basel, Switzerland

**Paulo Vale**

IPMA - Instituto Português do Mar e da Atmosfera, Lisboa, Portugal

**Pedro Baptista**

Centre for Research in Human Molecular Genetics, Department of LifeSciences, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal

**Pedro Rodrigues**

Centro de Ciências do Mar do Algarve, CCMAR, Faro, Portugal

**Pedro Santos**  
CBMA-Centre of Molecular and Environmental Biology, Department of Biology, University of Minho, Braga, Portugal

**Pedro S. Lazo**  
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología Del Principado de Asturias (IUOPA), Universidad de Oviedo, Spain

**Per Bruheim**  
Department of Biotechnology, Norwegian University of Science and Technology, Trondheim, Norway

**Phillip Cash**  
Division of Applied Medicine, University of Aberdeen, Scotland

**Philipp Hess**  
Institut Universitaire Mer et Littoral(CNRS - Université de Nantes - Ifremer), Nantes, France

**Philippe Castagnone-Sereno**  
Interactions Biotiques et Sante Vegetale, Sophia Antipolis cedex, France

**Pierscionek Barbara**  
School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, BT52 1SA, United Kingdom

**Pieter de Lange**  
DipartimentodiScienzedellaVita, SecondaUniversità degli Studi di Napoli, Caserta, Italy

**Qi Zhu**  
Dept. Electrical Engineering, ESAT/SCD, Katholieke Universiteit Leuven, Heverlee, Belgium

**Ralph Fingerhut**  
University Children`s Hospital, Swiss Newborn Screening Laboratory, Children`s Research Center, Zürich, Switzerland

**Ralf Hoffmann**  
Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Faculty of Chemistry and Mineralogy, Leipzig University, Germany

**Rawi Ramautar**  
Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands

**Ricardo Gutiérrez Gallego**  
Bioanalysis Group, Neuropsychopharmacology Program IMIM-Hospital del Mar & Department of Experimental and Health Sciences, University Pompeu Fabra, Spain

**Roman Zubarev**  
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

**Roque Bru Martinez**  
Plant Proteomics and Functional Genomics Group, Department of Agrochemistry and Biochemistry, Faculty of Sciences, Alicante University, Spain

**Rubén Armañanzas**  
Computational Intelligence Group, Departamento de Inteligencia Artificial, Universidad Politécnica de Madrid, Spain

**Ruddy Wattiez**  
Department of Proteomics and Microbiology, University of Mons (UMONS), Belgium

**Rune Matthiesen**  
Institute of Molecular Pathology and Immunology, University of Porto, Portugal

**Ruth Birner-Gruenberger**  
Medical University Graz, Austria

**Sabine Luthje**  
University of Hamburg, Biocenter Klein Flottbek, Hamburg, Germany

**Sadin Özdemir**  
Department of Biology, Faculty of Science and Arts, Siirt University, Turkey

**Salvador Ventura**  
Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Spain

**Sandra Kraljevic-Pavelic**  
University of Rijeka, Department of Biotechnology, Croatia

**Sebastian Galuska**  
Institute of Biochemistry, Faculty of Medicine, Justus-Liebig-University of Giessen, Germany

**Serge Cosnier**  
Department of Molecular Chemistry, Grenoble university/CNRS, Grenoble, France

**Serhat Döker**  
Cankiri Karatekin University, Chemistry Department, Cankiri, Turkey

**Shan He**  
Centre for Systems Biology, School of Biosciences and School of Computer Science, University of Birmingham, England

**Silvia Mazzuca**  
Plan Cell Physiology Laboratory, Department of Ecology, University of Calabria, Italy

**Simona Martinotti**  
Dipartimento di Scienze e Innovazione Tecnologica, DiSIT, University of Piemonte Orientale, Alessandria, Italy

**Soile Tapio**  
Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Radiation Biology, Neuherberg, Germany

**Sophia Kossida**  
Biomedical Research Foundation, Academy of Athens, Department of Biotechnology, Athens, Greece

**Spiros D. Garbis**  
Biomedical Research Foundation of the Academy of Athens, Center for Basic Research - Division of Biotechnology, Greece

**Steve Thany**  
Laboratoire Récepteurs et Canaux Ioniques Membranaires, UFR Science, Université d'Angers, France

**Stefania Orrù**  
University of Naples Parthenope, Naples, Italy

**Stefanie Hauck**  
Research Unit Protein Science, Helmholtz Center Munich, Neuherberg, Germany

**Stefano Curcio**  
Department of Engineering Modeling, Laboratory of Transport Phenomena and Biotechnology University of Calabria, Italy

**Susana Cristóbal**  
Department of Clinical and Experimental Medicine Faculty of Health Science Linköping University, Sweden

**Támara García Barrera**  
Departamento de Química y Ciencia de los Materiales, Facultad de Ciencias Experimentales, Universidad de Huelva, Spain

**Theodore Alexandrov**  
University of Bremen, Center for Industrial Mathematics, Germany

**Thole Züchner**  
Ultrasensitive Protein Detection Unit, Leipzig University, Center for Biotechnology and Biomedicine, Institute of Bioanalytical Chemistry, Germany

**Tiziana Bonaldi**  
Department of Experimental Oncology, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy

**Tomris Ozben**  
Akdeniz University Medical Faculty Department of Clinical Biochemistry, Antalya, Turkey

**Tsangaris George**  
Proteomics Research Unit, Center of Basic Research II Foundation of Biomedical Research of the Academy of Athens, Greece

**ÜnerKolukisaoglu**

Center for Plant Molecular Biology, Eberhard-Karls University Tübingen, Tübingen, Germany

**Valeria Bertagnolo**

Department of Morphology and Embryology University of Ferrara, Italy

**Vera Muccilli**

Dipartimento di Scienze Chimiche, Università di Catania, Catania, Italy

Veronica Mainini

Dept. Health Science, University of Milano-Bicocca, Faculty of Medicine, Monza (MB), Italy

**Vicenta Martínez-Zorzano**

Department of Biochemistry, Genetics and Immunology University of Vigo, Spain

**Virginie Brun**

French Atomic Energy Commission and *French National Institute for Health and Medical Research*, France

**Vittoria Matafora**

Biological Mass Spectrometry Unit, San Raffaele Scientific Institute, Milan, Italy

**Vladislav Khrustalev**

Department of General Chemistry, Belarussian, State Medical University, Dzerzhinskogo, Minsk, Belarus

**Xiaozhe Zhang**

Department of Medicine, University of Fribourg, Switzerland

**Yuri van der Burgt**

Leiden University Medical Center, Department of Parasitology, The Netherlands

---

**SOUTH AMERICA**

**Alessandro Farias**

Neuroimmunomodulation Group, department of Genetics, Evolution and Bioagents, University of Campinas - SP - Brazil

**Alexandra Sawaya**

Department of Plant Biology, Institute of Biology, UNICAMP, Campinas, São Paulo, Brazil

**Andréa P.B. Gollucke**

Hexalab/Catholic University of Santos, Brazil

**Arlindo Moura**

Department of Animal Science - College of Agricultural Sciences - Federal University of Ceara, Fortaleza, Brasil

**Bruno Lomonte**

Instituto Clodomiro Picado, Universidad de Costa Rica

**Deborah Schechtman**

Department of Biochemistry, Chemistry Institute, University of São Paulo, Brazil

**Edson Guimarães Lo Turco**

São Paulo Federal University, Brasil

**Elisabeth Schwartz**

Department of Physiological Sciences, Institute of Biological Sciences, University of Brasília, Brazil

**Fabio Ribeiro Cerqueira**

Department of Informatics and NuBio (Research Group for Bioinformatics), University of Vicoso, Brazil

**Fernando Barbosa**

Faculty of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo, Brazil

**Hugo Eduardo Cerecetto**

Grupo de Química Medicinal, Facultad de Química, Universidad de la República, Montevideo, Uruguay

**Luis Pacheco**

Institute of Health Sciences, Federal University of Bahia, Salvador, Brazil

**Mário Hiroyuki Hirata**

Laboratório de Biologia Molecular Aplicado ao Diagnóstico, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, Brazil

**Jan Schripsema**

Grupo Metabólica, Laboratório de Ciências Químicas, Universidade Estadual do Norte Fluminense, Campos dos Goytacazes, Brazil

**Jorg Kobarg**

Centro Nacional de Pesquisa em Energia e Materiais, Laboratório Nacional de Biociências, Brazil

**Marcelo Bento Soares**

Cancer Biology and Epigenomics Program, Children's Memorial Research Center, Professor of Pediatrics, Northwestern University's Feinberg School of Medicine

**Mario Palma**

Center of Study of Social Insects (CEIS)/Dept. Biology, Institute of Biosciences, University of São Paulo State (UNESP), Rio Claro - SP Brazil

**Rinaldo Wellerson Pereira**

Programa de Pós Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brazil

**Roberto Bobadilla**

BioSigma S.A., Santiago de Chile, Chile

**Rossana Arroyo**

Department of Infectomic and Molecular Biology, Center of Research and Advanced Studies of the National, Polytechnical Institute (CINVESTAV-IPN), Mexico City, Mexico

**Rubem Menna Barreto**

Laboratorio de Biología Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

**Vasco Azevedo**

Biological Sciences Institute, Federal University of Minas Gerais, Brazil

---

**NORTH AMERICA**

**Adam Vigil**

University of California, Irvine, USA

**Akeel Baig**

Hoffmann-La Roche Limited, Pharma Research Toronto, Toronto, Ontario, Canada

**Alexander Statnikov**

Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York

**Amosy M'Koma**

Vanderbilt University School of Medicine, Department of General Surgery, Colon and Rectal Surgery, Nashville, USA

**Amrita Cheema**

Georgetown Lombardi Comprehensive Cancer Center, USA

**Anthony Gramolini**

Department of Physiology, Faculty of Medicine, University of Toronto, Canada

**Anas Abdel Rahman**

Department of Chemistry, Memorial University of Newfoundland and Labrador St. John's, Canada

**Christina Ferreira**

Purdue University - Aston Laboratories of Mass Spectrometry, Hall for Discovery and Learning Research, West Lafayette, US

**Christoph Borchner**

Biochemistry & Microbiology, University of Victoria, UVic Genome British Columbia Proteomics Centre, Canada

**Dajana Vuckovic**  
University of Toronto, Donnelly Centre for Cellular + Biomolecular Research, Canada

**David Gibson**  
University of Colorado Denver, Anschutz Medical Campus, Division of Endocrinology, Metabolism and Diabetes, Aurora, USA

**Deyu Xie**  
Department of Plant Biology, Raleigh, USA

**Edgar Jaimes**  
University of Alabama at Birmingham, USA

**Eric McLamore**  
University of Florida, Agricultural & Biological Engineering, Gainesville, USA

**Eustache Paramithiotis**  
Caprion Proteomics Inc., Montreal, Canada

**FangXiang Wu**  
University of Saskatchewan, Saskatoon, Canada

**Fouad Daayf**  
Department of Plant Science, University of Manitoba, Winnipeg, Manitoba, Canada

**Haitao Lu**  
Washington University School of Medicine, Saint Louis, USA

**Hexin Chen**  
University of South Carolina, Columbia, USA

**Hsiao-Ching Liu**  
232D Polk Hall, Department of Animal Science, North Carolina State University Raleigh, USA

**Hui Zhang**  
Johns Hopkins University, MD, USA

**Ing-Feng Chang**  
Institute of Plant Biology, National Taiwan University, Taipei, Taiwan

**Irwin Kurland**  
Albert Einstein College of Medicine, Associate Professor, Dept of Medicine, USA

**Jagjit Yadav**  
Microbial Pathogenesis and Toxicogenomics, Laboratory, Environmental Genetics and Molecular, Toxicology Division, Department of Environmental Health, University of Cincinnati College of Medicine, Ohio, USA

**Jianbo Yao**  
Division of Animal and Nutritional Sciences, USA

**Jiaxu Li**  
Department of Biochemistry and Molecular Biology, Mississippi State University, USA

**Jiping Zhu**  
Exposure and Biomonitoring Division, Health Canada, Ottawa, Canada

**Jiri Adamec**  
Department of Biochemistry & Redox Biology Center, University of Nebraska, Lincoln Nebraska, USA

**Jiye Ai**  
University of California, Los Angeles

**John McLean**  
Department of Chemistry, Vanderbilt University, Nashville, TN, USA

**Joshua Heazlewood**  
Lawrence Berkeley National Laboratory, Berkeley, CA, USA

**Kenneth Yu**  
Memorial Sloan Kettering Cancer Center, New York, USA

**Laszlo Prokai**  
Department of Molecular Biology & Immunology, University of North Texas Health Science Center, Fort Worth, USA

**Lei Li**  
University of Virginia, USA

**Leonard Foster**  
Centre for High-throughput Biology, University of British Columbia, Vancouver, BC, Canada

**Madhulika Gupta**  
Children's Health Research Institute, University of Western Ontario London, ON, Canada

**Masaru Miyagi**  
Case Center for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, USA

**Michael H.A. Roehrl**  
Department of Pathology and Laboratory Medicine, Boston Medical Center Boston, USA

**Ming Zhan**  
National Institute on Aging, Maryland, USA

**Nicholas Seyfried**  
Emory University School of Medicine, Atlanta, USA

**Olgica Trenchevska**  
Molecular Biomarkers, Biodesign Institute at Arizona State University, USA

**Peter Nemes**  
US Food and Drug Administration (FDA), Silver Spring, USA

**R. John Solaro**  
University of Illinois College of Medicine, USA

**Rabih Jabbour**  
Science Application International Corporation, Maryland, USA

**Ramesh Katam**  
Plant Biotechnology Lab, Florida A and M University, FL, USA

**Robert L. Hettich**  
Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, USA

**Robert Powers**  
University of Nebraska-Lincoln, Department of Chemistry, USA

**Shen S. Hu**  
UCLA School of Dentistry, Dental Research Institute, UCLA Jonsson Comprehensive Cancer Center, Los Angeles CA, USA

**Shiva M. Singh**  
University of Western Ontario, Canada

**Susan Hester**  
United States Environmental Protection Agency, Durnam, USA

**Terry D. Cyr**  
Genomics Laboratories, Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, Health Products and Foods Branch, Health Canada, Ontario, Canada

**Thibault Mayor**  
Department of Biochemistry and Molecular Biology, Centre for High-Throughput Biology (CHiBi), University of British Columbia, Canada

**Thomas Conrads**  
USA

**Thomas Kislinger**  
Department of Medical Biophysics, University of Toronto, Canada

**Wan Jin Jahng**  
Department of Biological Sciences, Michigan Technological University, USA

**Wayne Zhou**  
Marine Biology Laboratory, Woods Hole, MA, USA

**Wei Jia**  
US Environmental Protection Agency, Research Triangle Park, North Carolina, USA

**Wei-Jun Qian**  
Pacific Northwest National Laboratory, USA

**William A LaFramboise**  
Department of Pathology, University of Pittsburgh School of Medicine Shadyside Hospital, Pittsburgh, USA

**Xiangjia Min**  
Center for Applied Chemical Biology, Department of Biological Sciences

Youngstown State University, USA

**Xiaoyan Jiang**

Senior Scientist, Terry Fox Laboratory, BC Cancer Agency, Vancouver, Canada

**Xu-Liang Cao**

Food Research Division, Bureau of Chemical Safety, Health Canada, Ottawa, Canada

**Xuequn Chen**

Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, USA

**Ye Fang**

Biochemical Technologies, Science and Technology Division, Corning Incorporated, USA

**Ying Qu**

Microdialysis Experts Consultant Service, San Diego, USA

**Ying Xu**

Department of Biochemistry and Molecular Biology, Institute of Bioinformatics, University of Georgia, Life Sciences Building  
Athens, GA, USA



SPECIAL ISSUE  
PROCEEDING ABSTRACTS OF THE 1<sup>st</sup> INTERNATIONAL  
CAPARICA CONFERENCE IN SPLICING (SPLICING 2016)

The content published in this issue was previously selected by the scientific committee to be presented at the 1<sup>st</sup> International Caparica Conference in Splicing, from 14 - 15 September 2016 in Caparica, Almada, Portugal. Only the Proceeding Abstracts with a copyright transfer agreement were reproduced.

# 1<sup>st</sup> International Caparica Conference in Splicing (SPLICING 2016)

Caparica – Lisbon, Portugal – 14<sup>th</sup>-16<sup>th</sup> September 2016

## **Comitees**

### Conference Chairs

**Carlos Lodeiro Espiño, PhD. FRSC**

UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.

**José Luis Capelo Martínez, PhD. FRSC**

UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.

### **Scientific Committee**

**Carlos Lodeiro Espiño, PhD. FRSC**

UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.

**José Luis Capelo Martínez, PhD. FRSC**

UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.

**Hugo Santos, PhD**

UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.

**Elisabete Oliveira, PhD**

UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.

**Javier Fernández-Lodeiro, PhD**

UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.

**Gilberto Igrejas, PhD**

Universidade de Trás-os-Montes e Alto Douro, Portugal.

**Benoit Chabot, PhD**

Department of Microbiology and Infectious Diseases; Faculty of Medicine and Health Sciences;  
Université de Sherbrooke, Sherbrooke, Quebec, Canada.

**Thomas Cooper, PhD**

Baylor College of Medicine, USA.

**Guillaume Hautbergue, PhD**

Department of Neuroscience; University of Sheffield, UK.

**Mario Guarracino, PhD**

Istituto di Calcolo e Reti ad Alte Prestazioni; Consiglio Nazionale delle Ricerche, Italy.

**Marcella Vacca, PhD**

Institute of genetics and Biophysics; Consiglio Nazionale delle Ricerche, Italy.

**Marta Milo, PhD**

Department of biomedical Science; University of Sheffield, UK.

### **Conference Secretariat**

**José Luis Capelo Martínez, PhD. FRSC**

UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.

**Susana Jorge**


UCIBIO-REQUIMTE, Chemistry Department, Universidade NOVA de Lisboa, Portugal.



## SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1<sup>st</sup> INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPLICING 2016)

### CONTENTS OF VOLUME 6 | ISSUE 2 | DECEMBER 2016

RBM4 promotes neuronal cell differentiation by modulating alternative splicing of signaling factors.....	1
The RNA-binding protein Arrest/Bruno regulates fibrillar myogenesis in <i>Drosophila</i> .....	2
Insights into protein splicing reaction steps by means of computational chemistry .....	3
Tumor-specific modulation of alternative splicing by small molecules that target SF3B1.....	4
Detrimental exon skipping of immunoglobulin transcripts in plasma cells: towards a new splicing therapy in the treatment of plasma cell disorders .....	5
Going Deep: Ultra-sensitive Computational Detection of Splicing Variation from a Single and from Multiple RNA-seq Samples .....	6
The interplay between mRNA translation and nonsense-mediated decay in transcripts with short open reading frames .....	7
The role of splicing factor gene mutation in craniofacial disorders .....	8
Transcriptional interference in human cells: exonization and intron retention.....	9
Intein PRP8 in pathogenic fungi: evolutionary aspects and splicing evaluation .....	10
Epithelial splicing regulatory proteins ESRP1 and ESRP2 correlate with splice signatures and outcome in human colorectal cancer	11
Frequent in vivo detection of HIV-1 RNAs of the 1 kb class using diverse 3' splice sites .....	12
Within the family of MELOE antigens, IRES-dependent translation conditions exclusive expression in melanoma cells and immunogenicity .....	13
Spliceosome inhibition as novel strategy against diffuse malignant peritoneal mesothelioma .....	14
The oxygenase Jmjd6 – a master regulator of SR-proteins?.....	15
The Significance of Splicing and Specific Intronic Elements for Intron-Mediated Enhancement .....	16
Blocking of iCLIP identified hnRNPA1 binding sites by splice switching oligonucleotides corrects aberrant splicing.....	17
Endogenized Transposable Elements Reshape the Human Transcriptome.....	18
Intergenic splicing in cancer and normal physiology .....	19
Functionally distinct ryanodine receptor variants generated by alternative splicing using GG/AG intron .....	20



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPlicing 2016)

## RBM4 promotes neuronal cell differentiation by modulating alternative splicing of signaling factors

W.-Y. Tarn, D. Dhananjaya, C.-H. Su, H.-C. Kuo, S.-I. Yu

Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Sec. 2, Nankang, Taipei, Taiwan

Available Online: 31 December 2016

---

### ABSTRACT

---

**Purpose:** RBM4 plays important roles in cell differentiation and cancer progression. We have previously reported that RBM4 promotes muscle and pancreas cell differentiation via its splicing regulatory activity (J. Cell Biol., 2011; Mol. Cell. Biol., 2013). We also investigated the role of RBM4 in neuronal differentiation and migration.

**Experimental description:** We used mouse embryonal carcinoma P19 cells, mouse neuronal progenitor cell lines, and human mesenchymal cells to investigate the role of RBM4 in neuronal cell differentiation. We also examined the role of RBM4 in neuronal cell migration during cortical development.


**Results:** Using mouse P19 cells as a neural differentiation model, we found that RBM4 modulates alternative splicing of the cell-fate determining factor Numb and thereby affects the expression of neuronal differentiation factor Mash1. Accordingly, ectopic RBM4 expression in neuronal progenitor cells increased Mash1 expression and promoted cell differentiation. RBM4 is also essential for neurite outgrowth of cortical neurons *in vitro*. RBM4-induced Numb isoforms can rescue neurite outgrowth defects of RBM4-depleted neurons. The above results demonstrate that RBM4 promotes the expression of specific Numb isoforms, which contribute to neuronal cell differentiation and neurite outgrowth (Mol. Biol. Cell, 2016). More recently, we found that RBM4 could promote neuronal differentiation of mesenchymal stem cells by modulating cell metabolic status as well as promote cell migration. We have identified the targets of RBM4 that are responsible for RBM4's functions in neuron.

**Conclusions:** We demonstrated that RBM4, through alternative splicing of signaling factors, executes its functions neuronal cell differentiation and cell migration.

---

**Keywords:** alternative splicing, neuronal cell differentiation, glucose metabolism, neuronal migration.

**Correspondence:** Woan-Yuh Tarn, Ph.D. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; E-mail: wtarn@ibms.sinica.edu.tw.



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPlicing 2016)

## The RNA-binding protein Arrest/Bruno regulates fibrillar myogenesis in *Drosophila*

M. L. Spletter<sup>1</sup>, C. Barz<sup>1</sup>, A. Yeroslaviz<sup>1</sup>, O. Nikonova<sup>1</sup>, C. Schönbauer<sup>1</sup>, B. H. Habermann<sup>1,2</sup>, F. Schnorrer<sup>1,2</sup>

<sup>1</sup> Muscle Dynamics group, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152, Martinsried, Germany. <sup>2</sup> IBDM—Institut de Biologie du Développement de Marseille, UMR 7288 Case 907, Parc Scientifique de Luminy, 13288 Marseille Cedex 9, France.

Available Online: 31 December 2016

### ABSTRACT

*Drosophila*, like vertebrates, has multiple types of muscles with different functional properties. In adult *Drosophila*, fibrillar muscles power flight, while tubular muscles coordinate jumping and walking. These muscle types differ both in patterns of gene expression and alternative splicing, but the mechanisms generating this diversity are not well understood. Our data shows that CELF-family member Arrest/Bruno controls flight-muscle specific differentiation by regulating an alternative splicing program downstream of Spalt Major (Salm). Salm regulates a diverse set of genes that determine fibrillar muscle physiology, and Arrest targets are responsible for proper growth and maturation of the sarcomere. Loss of Arrest results in hypercontraction due to missplicing of structural components including Strn-Mlck, Mhc, Up and WupA (TnI), leading to loss of muscle fibers in adult flies. As Arrest and its sarcomeric targets are evolutionarily conserved, similar principles may regulate mammalian muscle morphogenesis.

**Purpose:** Here we investigate the genetic mechanisms underlying the differentiation of muscle types, in particular the regulation of alternative splicing during muscle-type specific development.

**Experimental description:** In this study, we used mRNA-Seq to identify differences in gene expression and exon usage between wild-type and flies with a loss-of-function of either Salm or Arrest. Building on these results, we use fly genetics and confocal microscopy to characterize muscle phenotypes and verify expression patterns.


**Results:** We show that more than 200 fibrillar-specific genes are regulated by Salm. Strikingly, we also observe that Salm promotes a fibrillar-specific program of alternative splicing. Nearly 80% of the fibrillar specific exons regulated by Salm are also regulated by Salm target RNA-binding protein Arrest/Bruno. We verify regulation of fibrillar-specific isoform expression using fosmid-GFP reporters. Functionally, loss of Arrest causes a failure in sarcomere maturation and a misregulation of myosin function resulting in flightlessness, hypercontraction and muscle loss.

**Conclusions:** We identify Arrest/Bruno as the key fibrillar muscle specific splicing factor downstream of Salm, and show that the splicing program regulated by Arrest is essential for sarcomere growth and maturation as well as muscle function.

**Keywords:** CELF, alternative splicing, Arrest/Bruno, muscle development, sarcomerogenesis, *Drosophila*.

**Acknowledgements:** We thank Anne Ephrussi for reagents and the Bloomington and VDRC stock centres for fly stocks. We are grateful to Reinhard Fässler for generous support and to Bettina Stender for technical assistance. Our work was funded by the Max Planck Society, Humboldt, EMBO (688-2011 and YIP), NIH (5F32AR062477), HFSP and ERC (FP/2007-2013 310939).

**Correspondence:** Am Klopferspitz 18, 82152 Martinsried, Germany. spletter@biochem.mpg.de



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPlicing 2016)

## Insights into protein splicing reaction steps by means of computational chemistry

J. I. Mujika


Kimika Fakultatea, University of the Basque Country (UPV/EHU) and Donostia International Physics Center (DIPC), San Sebastian (Basque Country, Spain)

Available Online: 31 December 2016

### ABSTRACT

Protein splicing is a post-translational process in which a biologically inactive protein is activated by the release of a segment denoted as intein and by the joining of the two flanking segments, the exteins. [1] The process is auto-catalytic, what makes inteins appealing for many applications in biotechnology, bioengineering, or medicine. Therefore, a full understanding of its underlying mechanism is crucial for an optimal application of the process in any of these areas. The canonical mechanism of the process is well established and includes four steps (see Figure). However, how each step is chemically modulated is not fully understood, and more importantly, the specific roles played by the essential amino acids are still to be elucidated.


The research presented herein was carried out by means of computational chemistry. This field of the chemistry describes the system into an atomic level and therefore it is a very useful alternative to complement the experimental studies and get access into an information difficult to achieve by other techniques. The results [2,3] reveal a detailed description of the key steps and provide a comprehensible explanation of the catalytic roles played by the conserved amino acids.



### References:

- [1] K. V. Mills, M. A. Johnson, F. B. Perler, *J. Biol. Chem.* 2014 , 289 , 14498-14505.
- [2] J. I. Mujika, X. Lopez, A. J. Mulholland, *Org. Biomol. Chem.* 2012 , 10 , 1207-18.
- [3] J. I. Mujika, X. Lopez, A. J. Mulholland, *J. Phys. Chem. B* 2009 , 113 , 5607-16.

Correspondence: joni.mujika@ehu.eus



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPlicing 2016)

## Tumor-specific modulation of alternative splicing by small molecules that target SF3B1

Gang Wu, Liying Fan, Philip M. Potter

Departments of Chemical Biology and Therapeutics and Computational Biology. St Jude Children's Research Hospital. Memphis, TN, 38105, USA

Available Online: 31 December 2016

---

### ABSTRACT

---

**Purpose:** Recently several different classes of small molecules have been identified that interact with SF3B1. These agents induce changes in alternative splicing RNA (AS) that appear to be tumor-specific. We seek to understand the mechanism and consequences of such events in both tumor and normal cells.

**Experimental description:** Tumor cells were exposed to different agents that interact with SF3B1 and the effects on RNA splicing and the proteome have been documented. This was accomplished using a novel analysis pipeline designed to identify and validate AS isoforms in RNAseq datasets, and to correlate this data with proteomic analyses of the same samples.

**Results:** Using our RNAseq analysis pipeline, we have developed approaches to detect, identify and quantitate unique RNA species present in datasets obtained from drug- treated cells. These results indicate that different SF3B1 targeting agents induce different AS events, in a dose- and time-dependent manner.


**Conclusions:** Our results demonstrate that the cellular responses to different spliceosome targeting agents differ, even though they interact with the same component of this complex. Additionally, RNAs obtained from AS are translated into proteins of likely unique function. As a consequence, the latter are likely to significantly modulate cellular function.

---

**Keywords:** SF3B1, alternative splicing, RNAseq.

**Acknowledgements:** This work was supported in part by an NIH Cancer Center Core grant CA21765, and by the American Lebanese Syrian Associated Charities (ALSAC) and St. Jude Children's Research Hospital (SJCRH).

**Correspondence:** Philip M. Potter, Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, United States E-mail: phil.potter@stjude.org



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPlicing 2016)

## Detrimental exon skipping of immunoglobulin transcripts in plasma cells: towards a new splicing therapy in the treatment of plasma cell disorders

Nivine Srour, Mohamad Omar Ashi, Christophe Sirac, Michel Cogné and Laurent Delpy<sup>1</sup>

<sup>1</sup> Université de Limoges - CNRS UMR 7276, Limoges, France

**Available Online:** 31 December 2016

---

### ABSTRACT

---

Aberrantly rearranged immunoglobulin (Ig) genes are frequent and usually considered sterile and innocuous due to nonsense-mediated mRNA decay. Alternative splicing can however yield internally deleted proteins from such nonproductively V(D)J-rearranged loci.

We show that nonsense codons from variable (V) Ig exons promote exon-skipping and synthesis of V domain-less Ig kappa light chains. The expression of such truncated-Ig lacking V domain impaired plasma cell differentiation and antibody responses. Truncated-Ig have intrinsic toxic effects and induce ER stress-associated apoptosis in plasma cells (PCs). Altogether, we identify a "truncated-Ig exclusion" (TIE) checkpoint dampening PC differentiation by eliminating cells expressing non-functionally rearranged Ig alleles. The TIE-checkpoint thus mediates selection of long-lived PCs with limited ER stress supporting high Ig secretion (Srour et al, J Exp Med 2016).


Based on these results, a patent was applied to increase the production of truncated-Ig lacking variable domain using antisense oligonucleotides (AON). This exon skipping therapy could open new avenues for plasma cell neoplasms (including multiple myeloma) treatment.

---

**Keywords:** Exon skipping, Immunoglobulin, Antisense oligonucleotides, Splicing therapy.

**Acknowledgements:** This work was supported by grants from Fondation ARC (#PGA120150202338 and SFI20121205821), Ligue Contre le Cancer (comité Haute-Vienne), Comité d'Organisation de la Recherche sur le Cancer du Limousin (CORC) and Fondation pour la Recherche Médicale.

**Correspondence:** Laurent Delpy (laurent.delpy@unilim.fr), CNRS UMR 7276, 2 rue du Dr. Marcland, F-87025 Limoges, France, Fax # 33 555 435 897; Phone # 33 519 564 214



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPlicing (SPlicing 2016)

## Going Deep: Ultra-sensitive Computational Detection of Splicing Variation from a Single and from Multiple RNA-seq Samples

L. D. Florea<sup>1</sup>

<sup>1</sup> McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.

Available Online: 31 December 2016

### ABSTRACT

**Purpose:** The growing volume of RNA-seq data represents a vast resource that holds clues to gene alternative splicing. However, identifying splicing variation at great depth has been difficult: current transcript assembly methods can identify the major isoforms with very high accuracy at the expense of minor variants, or are sensitive but highly imprecise. Artifacts such as intronic reads, alignments to paralogs, and spurious matches can significantly affect the prediction. Cross-analyzing multiple data sets can provide additional power to distinguish signal from noise, however, all practical tools to date are designed to analyze one sample at a time.

**Experimental description:** Our group has developed tools for comprehensive detection and characterization of alternative splicing variation from RNA-seq data. We present two programs, the single-sample transcript assembler CLASS2 [1] and the multi-sample intron selector JULiP. CLASS2 uses read coverage information in a linear program to infer exons and build a splice graph, then selects a subset of paths in the graph using dynamic programming. JULiP employs a linear program to model intron inclusion rates and takes advantage of latent information in multiple samples to more comprehensively and accurately identify the true introns.

**Results:** CLASS2 has increased accuracy compared to other reference methods, on both simulated and real data, and can find up to twice as much splice variation compared to Cufflinks, at comparable or only slightly lower precision. It also incorporates an intronic noise filter, which makes it particularly well suited for analysis of rRNA-depleted libraries, in particular from FFPE samples, and to identify intron retention events. When applied to multi-sample RNA-seq sets, JULiP has significantly increased sensitivity, close to 90%, >30% higher compared to a single sample and >12% more than the cumulative set from all samples, whereas its precision is higher or comparable to the best of the programs. Additionally, JULiP is scalable and takes only over 1 min to analyze 100 RNA-seq data sets on a multi-computer cluster.

**Conclusions:** We described a suite of tools (<http://sourceforge.net/projects/Splicebox>) for accurate in depth detection of splice variation in single and multiple RNA-seq samples. Our methods are fast, scalable and accurate and can be effectively used to create comprehensive catalogs of splicing variation from the vast and varied collections of RNA-seq experiments.


**Keywords:** RNA-seq, alternative splicing, transcript assembly, linear programming.

**Acknowledgements:** NSF grants ABI-1356078 and IOS-1339134.

#### References:

[1] Song, L., S. Sabuncian, L. Florea. (2016) CLASS2: Accurate and efficient splice variant annotation from RNA-seq reads, *Nucl. Acids Res.*, pii: gkw158 (Advance access).

**Correspondence:** 1900 E Monument St, Welch 113, Baltimore, MD 21205, USA. Email: florea@jhu.edu



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPlicing (SPlicing 2016)

## The interplay between mRNA translation and nonsense-mediated decay in transcripts with short open reading frames

C. Onofre<sup>1,2</sup>, J. Menezes<sup>1,2</sup>, I. Peixeiro<sup>1,2</sup>, C. Barbosa<sup>1,2</sup>, L. Romão<sup>1,2</sup>

<sup>1</sup> Department of Human Genetics, Instituto Nacional de Saúde Doutor Ricardo Jorge, 1649-016 Lisboa, Portugal. <sup>2</sup> Biosystems & Integrative Sciences Institute (BioISI), Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.

Available Online: 31 December 2016

### ABSTRACT

Mammalian nonsense-mediated mRNA decay (NMD) is a splicing- and translation-dependent surveillance pathway that recognizes and selectively degrades mRNAs carrying premature termination codons (PTCs). In addition, several studies have also implicated NMD in the regulation of steady-state levels of physiological mRNAs, and examples of natural NMD targets are transcripts containing upstream short open reading frames or long 3' untranslated regions.


The strength of the NMD response appears to reflect multiple determinants on a target mRNA. In general, the location of a PTC greater than 50 nucleotides upstream to the last exon-exon junction constitutes a major determinant of NMD. However, we have reported that human mRNAs with a PTC in close proximity to the translation initiation codon (AUG-proximal PTC), and thus, with a short open reading frame, can substantially escape NMD. Our data support a model in which cytoplasmic poly(A)-binding protein 1 (PABPC1) is brought into close proximity with an AUG-proximal PTC via interactions with the translation initiation complexes. This proximity of PABPC1 to the AUG-proximal PTC allows PABPC1 to interact with eRF3 with a consequent enhancement of the release reaction and repression of the NMD response. Here, we present strong evidence that the eIF3 is involved in delivering eIF4G-associated PABPC1 into the vicinity of the AUG-proximal PTC. In addition, we dissect the biochemical interactions of the eIF3 subunits in bridging PABPC1/eIF4G complex to the 40S ribosomal subunit. Together, our data provide a framework for understanding the mechanistic details of PTC definition and translation initiation.

**Keywords:** Nonsense-mediated mRNA decay; translation; premature termination codon (PTC).

**Acknowledgements:** This work was partially supported by Fundação Luso-Americana para o Desenvolvimento and Fundação para a Ciência e a Tecnologia (UID/MULTI/04046/2013 to BioISI from FCT/MCTES/PIDDAC).

**Correspondence:** Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Av. Padre Cruz, 1649-016 LISBOA, PORTUGAL; luisa.romao@insa.min-saude.pt.





# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPlicing (SPlicing 2016)

## The role of splicing factor gene mutation in craniofacial disorders

Moses Tandiono, Huw Thomas, Robert Baines, Cortland Linder, Kathryn Hentges, William Newman and Raymond O'Keefe

Faculty of Life Sciences and Manchester Centre for Genomic Medicine, The University of Manchester, United Kingdom

Available Online: 31 December 2016

---

### ABSTRACT

---

**Purpose:** The related craniofacial disorders Burn-McKeown Syndrome (BMKS) and MandibuloFacial Dysostosis Guion-Almeida type (MFDGA) are characterized by mandibular and malar hypoplasia, microcephaly, choanal atresia, external ear anomalies and other variable craniofacial and developmental defects. We have recently found that mutations that reduce expression of the U5 snRNP gene TNXL4A (DIB1) cause BMKS1. Interestingly, reduced expression of the U5 snRNP gene EFTUD2 (SNU114) causes MFDGA providing a strong link between U5 snRNP function and these craniofacial disorders, as well as a possible functional link between the Dib1 and Snu114 proteins during splicing. The mechanisms by which reduced expression of essential splicing factor genes, required for splicing all pre-mRNAs, bring about these particular craniofacial disorders are unclear. Our hypothesis is that reduced expression of DIB1 and SNU114 partially disrupts spliceosome function, resulting in missplicing of a subset of pre-mRNAs required during craniofacial development.

**Experimental description:** To address this hypothesis we have initially used yeast models of BMKS and MFDGA.


**Results:** Reduced expression of DIB1 and SNU114 in yeast does indeed cause missplicing of some pre-mRNAs but not others. In addition, we have found that reduced expression of DIB1 and SNU114 cause defects in snRNP assembly, including defects in tri-snRNP formation. We are currently investigating whether there is a functional link between Dib1 and Snu114 within the spliceosome. Growth of yeast models under a variety of conditions has identified conditions that induce ER stress as affecting growth of yeast models more than wild type cells. Related to ER stress sensitivity we have identified the intron containing gene, CNB1, as being particularly susceptible to reduced DIB1 and SNU114 expression. CNB1 codes for Calcineurin B, the regulatory subunit of calcineurin, a Ca<sup>++</sup>/calmodulin-regulated type 2B protein phosphatase. Calcineurin is important in the signaling pathway that promotes cell survival under stress.

**Conclusions:** Reduced levels of Calcineurin cause ER stress, which in turn induces apoptosis. Apoptosis of neural crest cells, at certain times and locations during development, is critically important for proper craniofacial development. We are now investigating whether patient cells are more sensitive to ER stress and setting up mouse models to determine exactly how reduced DIB1 and SNU114 expression leads to BMKS and MFDGA.

**Keywords:** U5 snRNP, yeast, Snu114, Dib1, human disease.

**Acknowledgements:** This work is funded by the BBSRC.

**Correspondence:** Faculty of Life Sciences, The University of Manchester, Michael Smith building, Oxford Road, Manchester, M13 9PT, UK. E-mail: rokeefe@manchester.ac.uk.



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPLICING 2016)

## Transcriptional interference in human cells: exonization and intron retention

S. Raudsepp, M. Kanemägi, M. Speek

Department of Gene Technology, Faculty of Science, Tallinn University of Technology, Akadeemia tee 15, Tallinn 12618, Estonia

Available Online: 31 December 2016

---

### ABSTRACT

---

**Purpose:** Recent data suggest that retroelement insertions into exons and introns of genes induce different types of genetic disease, including cancer. Among other effects, retroelements interfere with the expression of genes by inducing alternative splicing via exon skipping and exonization using cryptic splice sites. These molecular effects may be explained by transcriptional interference (TI) and exon definition in RNA splicing. We have studied TI effects induced by L1 retrotransposon in the human *NCAM1* locus.

**Experimental description:** We analyzed the nucleosome occupation in *NCAM1* exon-intron 9 by mapping micrococcal nuclease accessible sites. To reveal TI effects, RNA polymerase II (RNAP II) pausing sites and “transcription bubble” locations, we used chromatin immunoprecipitation and probing with potassium permanganate coupled with ligation-mediated PCR.


**Results:** Our results show that changes in nucleosome positioning could result in changes in TI, that is intron retention and polyadenylation, induced by L1. In the analysis of the selected gene, we determined the locations of transcription bubbles and RNAP II occupancy upstream to the L1. These results show that RNAP II transcriptional pausing takes place at discrete regions in accordance with experimentally determined locations of transcription bubbles.

**Conclusions:** We conclude that nucleosome occupation plays a key role in the TI induced by L1 retrotransposon. The two TI effects (intron retention and cryptic polyadenylation) observed in our analysis are consistent with RNAP II pausing in the intron upstream to L1. Therefore, we believe that intronic L1 affects RNAP II elongation by regulating gene transcription through “sitting-duck” and/or roadblock mechanism.

---

**Keywords:** Transcriptional interference, L1 retrotransposon, intron retention, nucleosome occupation.

**Correspondence:** Mart Speek, Dept. of Gene Technology, Tallinn University of Technology, Akadeemia tee 15, rm 129, Tallinn 12618, Estonia. Email: mart.speek@ttu.ee



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPlicing (SPlicing 2016)

## Intein PRP8 in pathogenic fungi: evolutionary aspects and splicing evaluation

Eduardo Bagagli<sup>1</sup>, Hans Garcia-Garces<sup>1</sup> and Raquel Cordeiro Theodoro<sup>2</sup>

<sup>1</sup>Dept of Microbiology and Immunology, IBB-UNESP, Botucatu, SP, Brazil. <sup>2</sup> Dept of Cellular Biology and Genetics, UFRN, Natal, RN, Brazil

Available Online: 31 December 2016

### ABSTRACT

Inteins are intervening DNA sequences that are translated in frame with the host coding gene and then self-excised through protein splicing, which also ligates the N and C terminals of the host protein by peptide bonds, restoring its functionality. Besides their splicing domain, inteins might also contain an internal homing endonuclease (HE) domain, making them mobile elements. Inteins are usually found at conserved sites of housekeeping proteins that have vital functions in the cell, such as DNA and RNA polymerases, aminoacyl tRNA synthetases, recombinases, topoisomerases, helicases and essential components of the spliceosome, including the protein Prp8. Some extant hypotheses for this distribution are supported by the mobility of inteins by the homing cycle, while the inteins have been considered sophisticated parasitic genetic elements. One example of a domesticated intein is well known in *Saccharomyces cerevisiae*, namely the HO gene that has gained a well-defined function in the yeasts, by acting as site-specific endonuclease that initiates mating-type interconversion. Some recent works also indicate a possible function for inteins in the post-translational regulation of gene expression. Nevertheless, we are far from a complete understanding of why inteins have persisted in different housekeeping host proteins, mainly in unicellular organisms, over millions of years. For practical purposes, inteins proved to be valuable not only for protein biotechnology and phylogenetic studies, but also promising as a therapeutic drug target.


The PRP8 intein occurs in the protein Prp8, the main component of eukaryotic spliceosome, implicated in the editing of pre-messenger RNAs. This intein has been found in important fungal pathogens, including *Cryptococcus neoformans* (Basidiomycota, Tremellales), *Aspergillus fumigatus* (Ascomycota, Eurotiales), several members of the families *Artrodermataceae* and *Ajellomycetaceae* (Ascomycota, Onygenales), such as the dermatophytes species, *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Emmonsia parva*, *Paracoccidioides brasiliensis* and *P. lutzii*. In fact, the PRP8 intein profiles, which might occur in a mini (containing just the splicing domain) or full condition (containing the splicing and the HE domains) in these fungal lineages, have been used as a simple and efficient molecular marker for phylogenetically defining and/or distinguishing the related and cryptic species that occur in these fungal groups.

The splicing function of the PPR8 inteins from *B. dermatitidis*, *E. parva*, *P. brasiliensis* and *P. lutzii* has been evaluated by our group, in a non-native recombinant protein context by inserting the intein between a Maltose Binding Protein and a Thioredoxin, in *E. coli* cells. All PRP8 inteins proved to be active in this model, suggesting their usefulness for screening drugs that inhibit the intein excision in these important fungal pathogens.

**Keywords:** Intein, PRP8, spliceosome, self-splicing, Onygenales fungi

**Acknowledgements:** Financial Support: CNPq 306590/2015-8.

**Correspondence:** Eduardo Bagagli, Dept Microbiol and Imunol, IBB/UNESP, Botucatu, SP, Brazil. CEP 18.618-970.



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPlicing (SPlicing 2016)

## Epithelial splicing regulatory proteins ESRP1 and ESRP2 correlate with splice signatures and outcome in human colorectal cancer

Klaus Holzmann<sup>1</sup>, Abigail J. Deloria<sup>1</sup>, Philip Kienzl<sup>1</sup>, Justyna Łopatecka<sup>1</sup>, Lingeng Lu<sup>2</sup>, Brigitte Marian<sup>1</sup>, Stefan Stättner<sup>3</sup>

<sup>1</sup> Division of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University Vienna, Borschkegasse 8a, 1090 Vienna, Austria. <sup>2</sup> Department of Chronic Disease Epidemiology, Yale School of Public Health, School of Medicine, Yale Cancer Center, Yale University, 60 College Street, New Haven, CT 06520-0834 USA. <sup>3</sup> Department of Surgery, Paracelsus Medical University Salzburg, Salzburg, Austria.

Available Online: 31 December 2016

---

### ABSTRACT

---

**Purpose:** Master splice regulators ESRP1 and ESRP2 are implicated in alternative mRNA splicing programs important for epithelial-mesenchymal transition (EMT) and tumor progression. ESRP1 was identified in colorectal cancer (CRC) as tumor suppressor, but the prognostic value of ESRPs and relation with mesenchymal splice variants is not clear.

**Experimental description:** Tumor tissue and adjacent non-neoplastic colorectal epithelium were analyzed by qPCR from 68 CRC cases and compared with FGFR, CD44, ENAH and CTNND1(p120-catenin) gene splice patterns, clinical data and outcome. ESRP1 expression was evaluated by immunohistochemistry.

**Results:** Here, we identified reduced expression of both ESRPs in primary CRC tissue, associated with shorter patient survival and switch to mesenchymal gene expression signature. We observed in CRC cell models with conditional ESRP1 expression similar splice signatures of fibroblast growth factor receptors FGFR1-3 and genes important for EMT. ESRP1 was validated in silico as independent prognostic marker by public gene expression data from CRC patients of The Cancer Genome Atlas project.


**Conclusions:** Our study supports the role of ESRPs as tumor suppressors in CRC, important as conflicting associations with breast and pancreatic cancer patient outcome exists. We concluded that ESRPs are promising candidate biomarkers for early detection, diagnosis and prognosis of CRC.

**Keywords:** colorectal cancer, epithelial splicing regulatory protein, overall survival, prognostic marker

**Acknowledgements:** Thanks to members of the Department of Pathology (SMZ South, Kaiser Franz Josef Hospital, Vienna, Austria) for diagnostic support. Stefan Stättner and Klaus Holzmann were supported by the Medical Scientific Fund of the Mayor of Vienna #10091 and by the Herzfelder'sche Familienstiftung.

*This work has been published as full manuscript at Oncotarget. 2016 Sep 16. doi: 10.18632/oncotarget.12070*

**Correspondence:** Klaus Holzmann, Borschkegasse 8a, 1090 Vienna, Austria, email: klaus.holzmann@meduniwien.ac.at



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPICING (SPICING 2016)

## Frequent in vivo detection of HIV-1 RNAs of the 1 kb class using diverse 3' splice sites

Elena Delgado<sup>1</sup>, Yolanda Vega<sup>1</sup>, Cristina Carrera<sup>1</sup>, Carolina Arcones<sup>1</sup>, Ana Mariño<sup>2</sup>, Hortensia Álvarez<sup>2</sup>, Antonio Ocampo<sup>3</sup>, Celia Miralles<sup>3</sup>, Sonia Pérez-Castro<sup>3</sup>, Miguel Thomson<sup>1</sup>

<sup>1</sup> HIV Biology and Variability Unit. Centro Nacional de Microbiología. Instituto de Salud Carlos III. Carretera Majadahonda-Pozuelo, Km. 2. 28220 Majadahonda, Madrid, Spain. <sup>2</sup> Hospital Arquitecto Marcide. Ferrol, A Coruña, Spain. <sup>3</sup> Complejo Hospitalario Universitario de Vigo. Vigo, Pontevedra, Spain.

Available Online: 31 December 2016

### ABSTRACT

**Purpose:** All HIV-1 RNAs are transcribed from a single promoter and are processed through a complex splicing mechanism resulting in a great diversity of transcripts. According to splicing events involved in their generation, HIV-1 RNAs have been usually classified in three major categories: unspliced (~9 kb); singly spliced (~4 kb); and doubly spliced (~2 kb). We recently described a fourth RNA class, of ~1 kb, using 3' splice sites (3'ss) near the 3' end of the viral genome, within Nef coding sequence. Here we examine in vivo splice site usage for generation of HIV-1 1-kb RNAs.

**Experimental description:** Total RNA was extracted either from peripheral blood mononuclear cells (PBMCs) (n=14) or from immunomagnetically-separated CD4+CD25+ lymphocytes (n=19) from HIV-1-infected individuals. HIV-1 1-kb RNAs were amplified by RT-PCR followed by nested PCR using primers recognizing sequences near both ends of the HIV-1 genome. Sequences of PCR products were obtained either by direct sequencing of bands extracted from agarose gels or by clone sequencing.


**Results:** In clones from CD4+CD25+ lymphocytes, 8 different HIV-1 1-kb RNAs were detected in 7 (37%) of 19 individuals. Notably, in 6 (32%) individuals, clones from 1-kb RNAs were more abundant than clones from doubly spliced 2-kb RNAs coamplified in the same reaction. In samples in which 1-kb RNAs were amplified from PBMCs and directly sequenced, 9 1-kb RNAs were detected in 7 (50%) of 14 individuals. 1-kb RNAs used 13 different 3'ss, five of them previously reported and 8 newly identified. One RNA contained one exon in the antisense orientation between two sense-oriented exons. All identified 3'ss had the usual elements of metazoan 3'ss: an AG immediately upstream and a pyrimidine-rich tract further upstream. A majority of 1-kb RNAs were predicted to code for a 33-34 amino acid peptide at the C-terminus of Nef protein, but 6 lacked predicted coding capacity. Phylogenetic sequence analyses revealed that viruses in which 1 kb RNAs were detected belonged to 5 subtypes and 3 recombinant forms.

**Conclusions:** HIV-1 1-kb spliced RNAs using diverse 3'ss near the 3' end of the viral genome are frequently detected in vivo in viruses of different genetic forms. Although a majority potentially code for a C-terminal Nef peptide, they frequently lack coding potential. A hypothetical function of these RNAs mediated by sequestering cellular miRNAs targeted to the 3' untranslated region of HIV-1 mRNAs is proposed.

**Keywords:** HIV-1, splicing, 1 kb RNAs, subtypes.

**Acknowledgements:** This work was funded through grants SAF2010-20961 and SAF2013-48488-P, Plan Nacional de I+D+I, Ministry of Economy and Competitiveness, Spain. We thank the personnel at the Genomic Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, for technical help in sequencing.

**Correspondence:** Miguel Thomson (mthomson@isciii.es).



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPLICING 2016)

## Within the family of MELOE antigens, IRES-dependent translation conditions exclusive expression in melanoma cells and immunogenicity

M. Charpentier<sup>1</sup>, M. Croyal<sup>3</sup>, D. Carbonnelle<sup>1</sup>, A. Fortun<sup>1</sup>, L. Florenceau<sup>1,2</sup>, M. Krempf<sup>3</sup>, N. Labarrière<sup>1</sup>, F. Lang<sup>1</sup>

<sup>1</sup> CRCNA INSERM U892, CNRS 6299, University of Nantes – Labex IGO. Nantes, France. <sup>2</sup> Nantes Hospital. Nantes, France.

<sup>3</sup> INRA, UMR 1280, CRNH. Nantes, France

Available Online: 31 December 2016


### ABSTRACT

We have previously reported that 2 melanoma antigens, MELOE-1 and MELOE-2 involved in T cell immunosurveillance of melanoma were translated from the polycistronic mRNA *meloe* by IRES-dependent mechanisms. We now explored whether upstream ORFs from this mRNA could be translated by a classical cap-dependent mode and indeed found that the most upstream ORF, named MELOE-4 (54 aa), was very efficiently translated in melanoma cells. Using melanoma cell lines transfected with various eGFP-tagged MELOE constructs, we could evidence that expression of MELOE-4 was more than 100 times higher than that of MELOE-1 in melanoma cells. We have previously shown that melanocytes also express *meloe* mRNA but are not recognized by MELOE-1 or MELOE-2 specific T cell clones suggesting that IRES-dependent translation of MELOE-1 and MELOE-2 is not activated in these cells. In contrast, we documented the presence of MELOE-4 in 4 melanocyte cell lines by mass spectrometry. This presence argues in favor of MELOE-4 as the physiological product of *meloe* mRNA in melanocyte.

We then questioned the immunogenicity of MELOE-4 by exploring the CD8 and CD4 T cells repertoire against this antigen in healthy subjects in comparison to the frequent T cell repertoire against MELOE-1 that we described previously. Using an in vitro protocol of accelerated DC differentiation and maturation, we stimulated PBMC from 4 healthy donors with overlapping peptides from either MELOE-1 or MELOE-4 and tested CD4 and CD8 T cell reactivities upon restimulation by INF $\gamma$  intracellular staining. In marked contrast with the high frequencies of CD4 and CD8 T cell responses against MELOE-1 in all 4 healthy donors, we found no CD8 and very rare CD4 T cell responses against MELOE-4. This suggests an immune tolerance towards this antigen that would be consistent with its expression in normal melanocytes. In conclusion, despite its high expression in melanoma cells, the classically translated MELOE-4 antigen represents a poor target for T cell immunotherapy because of its expression profile and very low immunogenicity. On the other hand, IRES-dependent MELOE antigens represent the best T cell targets for immunotherapy due to their very specific expression by melanoma cells and high immunogenicity. This prompts us to explore other IRES-dependent antigens as target for immunotherapy in cancer.

**Keywords:** IRES, polycistronic RNA, melanoma antigen

**Correspondence:** francois.lang@univ-nantes.fr.



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPlicing 2016)

## Spliceosome inhibition as novel strategy against diffuse malignant peritoneal mesothelioma

R. Sciarriello<sup>1,2,3</sup>, V.E. Gomez<sup>3</sup>, M. Pennati<sup>6</sup>, A. Wojtuszkiewicz<sup>1,2</sup>, G.J.L. Kaspers<sup>1,2</sup>, C. Molthoff<sup>4</sup>, N. Zaffaroni<sup>6</sup>, G.J. Peters<sup>3</sup>, G. Jansen<sup>5</sup>, J. Cloos<sup>1,2</sup>, E. Giovannetti<sup>3,7</sup>

<sup>1</sup> Department of Hematology, CCA - VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.

<sup>2</sup> Department of Pediatric Oncology - CCA - VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam.

<sup>3</sup> Department of Medical Oncology - CCA - VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam.

<sup>4</sup> Department of Radiology & Nuclear Medicine - VU University Medical Center, Location Radionuclide Center, De Boelelaan 1085c, 1081 HV Amsterdam. <sup>5</sup> Department of Rheumatology - CCA - VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam. <sup>6</sup> Fondazione IRCCS - Istituto Nazionale dei Tumori, via Venezian 1, 20133, Milan, Italy. <sup>7</sup> Cancer Pharmacology Lab - AIRC Start-Up Unit - University of Pisa - Ospedale di Cisanello, Edificio 6, via Paradisa 2, 56124, Pisa, Italy.

**Available Online:** 31 December 2016

### ABSTRACT

**Purpose:** Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive tumor that affects the lining of the abdomen, characterized by late clinical symptoms and poor prognosis. Systemic chemotherapy together with cytoreductive surgery and intraperitoneal hyperthermic therapy has been introduced as the best treatment option over the last decade, resulting in an overall 5-year survival rate of approximately 50%. To further increase survival, novel drugs targeting key molecular factors in DMPM are warranted. Analogous to pleural mesothelioma, such a factor may be alternative splicing which can be modulated by inhibiting the SF3B subunit of the spliceosome. This strategy is an emerging therapeutic opportunity for a number of solid tumors and hematological malignancies. In particular, the spliceosome inhibitor Pladienolide B (PB) has low nanomolar IC50 values against a range of human cancer cell lines and leukemic cells, but no data are available regarding its antitumor efficacy in DMPM.

The present study investigates (1) the activity of PB (alone or in combination with standard chemotherapeutics) in primary peritoneal mesothelioma cells through *in vitro* and *in vivo* assays, and (2) the molecular mechanisms of splicing inhibition through whole-genome RNA-seq and PCR of selected genes involved in apoptosis and invasion.


**Experimental description:** The antiproliferative effect of PB was investigated using the SRB assay on two primary mesothelioma cell cultures (MESOII and STO), obtained from resected tumors with well-annotated clinical characteristics. Further *in vitro* studies were performed to evaluate the pro-apoptotic and anti-invasive activities, while splicing profiles of treated and untreated cells were determined with RNA-seq.

**Results:** PB impaired DMPM cell growth in a dose-dependent manner, with IC50 values of  $1.57 \pm 0.30$  nM in MESOII and  $1.18 \pm 0.16$  nM in STO ( $n=3$ , mean  $\pm$  standard deviation). The specific activity on the spliceosome was demonstrated by PB induced time- and dose-dependent alterations of splicing patterns for several apoptotic genes, such as Mcl-1, Bcl-X, Fas, and for the pro-metastatic tyrosine kinase receptor RON, which was shifted to its un-spliced and non-functional variant. In addition, RNA-seq showed several differentially expressed alternatively spliced genes in PB treated samples. The DMPM cells have also been genetically engineered to express Firefly- and Gaussia- luciferases, enabling monitoring of tumor growth inhibition by PB in *in vivo* orthotopic models.

**Conclusions:** These data provide evidence that PB has a strong antitumor activity against relevant models of DPMP, associated with modulation of splicing, induction of apoptosis and inhibition of invasion. RNA-seq represents a powerful tool for the identification of alternatively spliced genes that could serve as useful diagnostic markers as well as potential therapeutic targets for DMPM.

**Keywords:** mesothelioma, pladienolide, spheroid, orthotopic, novel therapeutics

**Correspondence:** Rocco Sciarriello, Department of Hematology/Medical Oncology, CCA - Cancer Center Amsterdam, room 4.04, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam. Phone: +316 526337700. E-mail: r.sciarriello@vumc.nl.



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPLICING 2016)

## The oxygenase Jmjd6 – a master regulator of SR-proteins?

J. Wesche<sup>1</sup>, S. Khn<sup>1</sup>, A. Wolf<sup>1</sup>

<sup>1</sup> Institute of Molecular Toxicology & Pharmacology, Helmholtz Zentrum Muenchen, Ingolstaedter Landstr. 1, 85764 Neuherberg, Germany

**Available Online:** 31 December 2016

---

### ABSTRACT

---


The Jumonji domain-containing protein 6 (Jmjd6) is a member of the superfamily of iron(II) and 2-oxoglutarate (2OG) dependent oxygenases. In recent years a large number of these 2OG oxygenases has been characterized to be involved in regulation of gene expression at different levels in humans. This includes epigenetic regulation, regulation of transcription and translation. The 2OG oxygenase Jmjd6 has been shown to be a nuclear localized protein with a JmjC-domain and has been described as a modulator of pre-mRNA splicing. The Jmjd6 protein is essential for embryonic development in vertebrates, including mice and zebra fish and is up-regulated in several cancers.

2OG oxygenases in humans catalyse transfer of molecular oxygen onto a substrate, which could either be an amino acid in a protein or a nucleotide in RNA or DNA. The Jmjd6 protein catalyses 2OG-dependent C-5 hydroxylation of lysine residues in splicing regulatory proteins, including U2AF65 and other SR- or SR-like proteins.

**Keywords:** Jmjd6, JmjC, Fe(II) and 2-oxoglutarate dependent oxygenases, alternative splicing, lysinehydroxylase, SR-proteins, alternative splicing

**Correspondence:** Alexander Wolf, Institute of Molecular Toxicology & Pharmacology, Helmholtz Zentrum Muenchen, Germany. Email: alexander.wolf@helmholtz-muenchen.de.





# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPlicing (SPlicing 2016)

## The Significance of Splicing and Specific Intronic Elements for Intron-Mediated Enhancement

T. Akua, O. Shaul

The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan 5290002, Israel

**Available Online:** 31 December 2016

---


### ABSTRACT

---

Introns stimulate gene expression in a wide range of organisms by increasing the levels of mature mRNA. Introns usually stimulate expression by a process termed intron-mediated enhancement (IME). This process has a great influence on gene expression in plants. The mechanism of IME is largely unknown. While splicing per se is not sufficient for IME, as evident from the fact that not all introns increase expression, it was not clear whether splicing of the enhancing introns is essential for enhancement. It is also not known why introns localized in the 5' untranslated region (5'UTR) are considerably longer than downstream introns. We showed that the leader intron (LI) of the Arabidopsis thaliana MHX gene (AtMHX) can substantially increase gene expression. This LI was utilized as a model to gain more knowledge on IME. We found that although AtMHX promoter showed almost no expression in the absence of this LI, this intron did not act as a transcriptional enhancer. This LI had different contributions to the expression mediated by different promoters. We also found that while splicing was essential for substantial IME, in the absence of splicing low-level enhancement could be obtained. The internal intron sequence played a significant role in mediating the low-level enhancement of the unspliced LI. Interestingly, we identified in this LI an internal element that considerably increased the efficiency of mRNA translation, without affecting splicing. Moreover, the ability of this intronic element to enhance translation was diminished by a minor downstream shift in the position of introns containing it from the 5'UTR into the coding sequence. This raised the possibility that some of the extra length of 5'UTR introns results from the presence of elements that enhance translation, and, moreover, from the ability of 5'UTR introns to provide preferable platforms for such elements over downstream introns.

---

**Correspondence:** orsha@mail.biu.ac.il.



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPlicing (SPlicing 2016)

## Blocking of iCLIP identified hnRNPA1 binding sites by splice switching oligonucleotides corrects aberrant splicing

Brage Storstein Andresen

Department of Biochemistry and Molecular Biology, University of Southern Denmark, Denmark

Available Online: 31 December 2016

---

### ABSTRACT

---


Correct splicing of exons with weak splice sites depends on a tight balance between positive and negative splicing regulatory elements (SREs). A large fraction of disease-causing mutations disrupt mRNA splicing by decreasing splice site strength or disrupting/creating SREs. We used iCLIP (individual-nucleotide resolution crosslink and immunoprecipitation) to create an in vivo binding map for the splicing regulatory protein hnRNP A1, which usually binds negative SREs to inhibit exon inclusion. HeLa cells with inducible expression of T7-tagged hnRNP A1 were UV irradiated generating irreversible crosslinks between RNA and RNA binding proteins allowing stringent purification of the bound RNA. The iCLIP libraries were subject to next-generation sequencing. We correlated the hnRNP A1 binding map with the hnRNP A1-regulated exons identified by hnRNP A1 knockdown and RNA-seq, and observed that the region immediately downstream of 5' splice sites is important for hnRNP A1-mediated exon repression.

We hypothesized that exons with weak splice sites, which are skipped due to a tipped balance between positive and negative SREs, could be reactivated by blocking iCLIP identified hnRNP A1 binding negative SREs using splice switching oligonucleotides (SSOs). We demonstrated the validity of this approach to activate a MTRR pseudoexon and the alternative exon 3 in SKA2 by SSO-mediated blocking of iCLIP-identified hnRNPA1 binding sites located immediately downstream of the 5' splice sites.

Interestingly, our iCLIP map revealed a hnRNP A1 binding site in intron 20 close to the 5' splice site of IKBKAP exon 20. Skipping of IKBKAP exon 20 causes familial dysautonomia (FD). FD is a recessive disease, affecting the sensory and autonomic nervous system and is frequent in Ashkenazi Jews. Almost all patients with FD are homozygous for a IVS20+6T>C mutation in IKBKAP, which decreases 5' splice site strength, causing exon 20 skipping. The iCLIP identified hnRNP A1 binding site was confirmed by in vitro studies. Therefore, we designed an SSO blocking the hnRNP A1 binding site in intron 20. Transfection of this SSO into FD patient fibroblasts fully restores IKBKAP exon 20 splicing.

Our study illustrates that the iCLIP generated hnRNP A1 binding map can be used to identify potential targets for SSO-based therapy.

---



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPlicing (SPlicing 2016)

## Endogenized Transposable Elements Reshape the Human Transcriptome

Manvedra Singh<sup>1</sup>, Laurence D. Hurst<sup>2</sup>, Zsuzsanna Izsvák<sup>1</sup>

<sup>1</sup> Max-Delbrück-Center for Molecular Medicine (MDC), Robert-Rössle-Strasse 10, 13125 Berlin, Germany. <sup>2</sup> University of Bath, Department of Biology and Biochemistry, Bath, Somerset, UK, BA2 7AY.

**Available Online:** 31 December 2016

---


### ABSTRACT

---

The evolutionary success of transposable elements (TEs) is powerfully underscored by the finding that about 45% of the human genome is TE-derived. While only a fraction of the human genome is actively mobile, TE-derived sequences can influence the human transcriptome in multiple ways. TEs, primarily endogenous retroviruses (ERVs), can provide alternative transcriptional regulatory sequences, including splice sites. ERVs can rewire the transcription of host genes, and contribute to novel chimeric transcripts. These alternative transcripts show spatio-temporal expression and also species-specific. Our data suggest that ERVs have massively reshaped the regulation of pluripotency during primate evolution.

In addition to retroelements, DNA transposons appear to modulate splicing by actively recruiting key factors of the splicing machinery. Surprisingly, our host-transposon interaction studies revealed a physical interaction between the piggyBac transposase protein and a host-encoded splicing factor. Curiously, certain domesticated piggyBac-like genes adopt this feature. This finding has important ramifications for the presence of domesticated piggyBAC-like elements in the human genome.

---



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

[HTTP://WWW.JIOMICS.COM](http://www.jiomics.com)



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPLICING 2016)

## Intergenic splicing in cancer and normal physiology

Hui Li

University of Virginia, Carter Harrison Bldg (MR6), Rm B524, Charlottesville, VA 22908, USA

**Available Online:** 31 December 2016

---

### ABSTRACT


---

Gene fusions and their fusion products were thought to be unique features of cancer, and produced solely by chromosomal rearrangement. We have demonstrated that RNA trans-splicing can produce identical fusion RNAs and in some cases, fusion proteins in normal cells. In a proof of principle experiment, we found a cancer-signature fusion RNA and protein transiently produced during normal myogenesis. We are using such cancer-signature fusions to track down the cell-of-origin for mysterious cancers.

In addition to trans-splicing, cis-SAGe (cis-splicing between adjacent genes) is another mechanism to produce intergenic spliced chimeric RNAs. By manipulating CTCF level combined with RNA-seq, we are identifying other cis-SAGe fusions.

To investigate the scope of chimeric RNAs in normal physiology, we finished curating and analyzing 291 RNA-seq datasets of 30 non-cancer tissues and cell types. Over 10,000 fusion RNA events were found, involving over 10% of human genome. We coined the word “fusionome” to describe the phenomenon. In addition to tissue specific fusions, we found a group of fusions being ubiquitously expressed and silencing them resulted in significant reduction in cell growth and motility in normal cells. We call them “house-keeping fusions”.

---



# JOURNAL OF INTEGRATED OMICS

A METHODOLOGICAL JOURNAL

HTTP://WWW.JIOMICS.COM



SPECIAL ISSUE: PROCEEDING ABSTRACTS OF THE 1ST INTERNATIONAL CAPARICA CONFERENCE IN SPLICING (SPLICING 2016)

## Functionally distinct ryanodine receptor variants generated by alternative splicing using GG/AG intron

Hiroshi Okamoto<sup>1,2</sup>, Shin Takasawa<sup>3</sup>, Yasuhiko Yamamoto<sup>1</sup>

<sup>1</sup> Kanazawa University, <sup>2</sup> Tohoku University, <sup>3</sup> Nara Medical University

**Available Online:** 31 December 2016

---

### ABSTRACT

---

Increases in the intracellular Ca<sup>2+</sup> concentration in pancreatic islets, resulting from the Ca<sup>2+</sup> mobilization from the intracellular source through ryanodine receptor (RyR), are essential for the insulin secretion by glucose. Cyclic ADP-ribose (cADPR), a potent Ca<sup>2+</sup> mobilizing second messenger synthesized by CD38, regulates the opening of RyR. A novel RyR cDNA (the islet-type RyR) was found to be generated from the type 2 RyR gene by the alternative splicing of exons 4 and 75. The islet-type RyR mRNA was expressed in a variety of tissues such as in pancreatic islets, cerebrum, and cerebellum, whereas the authentic type 2 RyR mRNA generated using GG/AG splicing of intron 75, was expressed in heart and aorta. The islet-type RyR caused a further increase in the caffeine-induced Ca<sup>2+</sup> release when expressed in HEK293 cells pre-treated with cADPR, thus suggesting that the novel RyR is an intracellular target for the CD38-cADPR signaling system in mammalian cells.

---

**\*Corresponding author:** Hisanori Kato, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan. Phone number: +81 358411607. Email Address: akatoq@mail.ecc.u-tokyo.ac.jp